TrialID,"Last Refreshed on","Public title","Scientific title",Acronym,"Primary sponsor","Date registration","Date registration3","Export date","Source Register","web address","Recruitment Status","other records","Inclusion agemin","Inclusion agemax","Inclusion gender","Date enrollement","Target size","Study type","Study design",Phase,Countries,"Contact Firstname","Contact Lastname","Contact Address","Contact Email","Contact Tel","Contact Affiliation","Inclusion Criteria","Exclusion Criteria",Condition,Intervention,"Primary outcome","Secondary outcome","Secondary ID","Source Name","Secondary Sponsor","Ethics Status","Ethics Approval Date","Ethics Contact Name","Ethics Contact Address","Ethics Contact Phone","Ethics Contact Email","results yes no","results date posted","results url link","results url protocol","results date completed","results date first publication","results summary","results baseline char","results adverse events","results outcome measures","results ipd plan","results ipd description","Prospective registration","Bridging flag truefalse","Bridged type"
ChiCTR2500096782,"10 February 2025","A retrospective study of non-interventional multicenter data was conducted to describe the clinical characteristics, diagnostic criteria, and treatment needs of patients with pyoderma gangrenosum (PG)","A retrospective study of non-interventional multicenter data was conducted to describe the clinical characteristics, diagnostic criteria, and treatment needs of patients with pyoderma gangrenosum (PG)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ",,"The First Affiliated Hospital of Zhejiang University School of Medicine",06/02/2025,"  20250206","10/03/2025 17:03:09",ChiCTR,https://www.chictr.org.cn/showproj.html?proj=261071,Recruiting,No,0,100,Both,07/02/2025,"Cases group:100;","Observational study",Cross-sectional,"Retrospective study",China,"Jianjun Qiao Shan Fang",,"79 Qingchun Road, Hangzhou 310003, Zhejiang, China",qiaojianjun@126.com,"+86 137 3554 2393","The First Affiliated Hospital of Zhejiang University School of Medicine","Inclusion criteria: 1. Patients meeting the diagnostic criteria for pyoderma gangrenosum.<br>2. Patients who received treatment and follow-up.<br>3. Complete medical records and clinical data.","Exclusion criteria: 1. Patients with unclear diagnosis.<br>2. Patients with incomplete medical records and clinical data.","pyoderma gangrenosum","Cases group:None;","Diagnostic criteria;","Demographic characteristics;Treatment method;",,"National Natural Science Foundation of China",,Approved,06/12/2024,"lili li","79 Qingchun Road, Hangzhou 310003, Zhejiang, China","+86 571 8723 3418",,,,,,,,,,,,Yes,,Yes,False,"          "
CTIS2024-517155-13-00,"10 December 2024","A double-blind, placebo-controlled, randomized withdrawal study of canakinumab in pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome","A double-blind, placebo-controlled, randomized withdrawal study of canakinumab in pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome - PAPA-Can                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      ",,"IRCCS Istituto Giannina Gaslini",04/09/2024,"  20240904","10/03/2025 17:03:09","Clinical Trials Information System",https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-517155-13-00,Recruiting,No,0,65+,"Female: yes Male: yes",01/01/1900,24,"Interventional clinical trial of medicinal product","Controlled: no Randomised: no Open: no Single blind: no Double blind: no Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: no Number of treatment arms in the trial:","Human pharmacology (Phase I): No Therapeutic exploratory (Phase II): No Therapeutic confirmatory - (Phase III): Yes Therapeutic use - (Phase IV): No",Italy,"Marco Gattorno",,,marcogattorno@gaslini.org,003901056362793,"IRCCS Istituto Giannina Gaslini","Inclusion criteria: Clinical diagnosis of PAPA with active flare at the time of enrolment., Mutation of the PSTPIP1 gene., Patient’s written informed consent from those = 18 years of age must be obtained before any assessment is performed. Parent or legal guardian’s written informed consent and child’s assent, if appropriate, are required before any assessment is performed for patients < 18 years of age., Male and female patients.","Exclusion criteria: Use of the following therapies: a. Glucocorticoids (prednisone equivalent > 0.2 mg/kg/day [or greater than the maximum of 10 mg/ day for children over 60 kg]) within 1 week prior to Baseline b. Anakinra within 72 hours prior to Baseline c. Other biologics (including canakinumab) or immunosuppressants 2 half-life prior to Baseline., Female adolescents (=18 years of age) of childbearing potential who do not agree to abstinence or, if sexually active, do not agree to the use of contraception as defined in the exclusion criterion for women of child bearing potential., Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing of study treatment., Known allergy or hypersensitivity to any component the IMP, History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in-situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases., Any conditions or significant medical problems which in the opinion of the investigator immunocompromises the patient and/ or places the patient at unacceptable risk for immunomodulatory therapy such as: a. Absolute neutrophil count <1.0 x 109/L or below b. Thrombocytopenia Platelets <10.0 x 109/L c. Any active or recurrent bacterial, fungal (with exception of onychomycosis) or viral infection. At least 1 month should elapse between the complete resolution of a severe infection, requiring hospitalization or systemic antibiotic therapy before the inclusion in the study d. Presence of Human Immunodeficiency Virus (HIV) infection, Hepatitis B (HBsAg) or Hepatitis C (HCV) infections based on screening lab results specific hepatitis serology that leads to exclusion. e. Clinical evidence or history of multiple sclerosis or other demyelinating diseases, or Felty’s syndrome, History or evidence of tuberculosis (TB) (active or latent) infection or one of the risk factors TB such as but not limited or exclusive to: a. History of any of the following: residence in a congregate setting (e.g. jail or prison, homeless shelter, or chronic care facility), substance abuse (e.g. injection or non-injection); health-care workers with unprotected exposure to patients who are at high risk of TB or patients with TB disease before the identification and correct airborne precautions of the patient, or b. Close contact (i.e. share the same air space in a household or other enclosed environment for a prolonged period (days or weeks, not minutes or hours) with a person with active pulmonary TB disease within the last year, or c. Evidence of TB infection (active or latent) determined by positive QuantiFERON (QFT-TB G In-Tube) test or positive Purified Protein Derivative (PPD) test (=5 mm induration) at screening or within 2 months prior to the screening visit, according to the national guidelines. If presence of TB infection (active or latent) is established then treatment for TB as per national guidelines must have been initiated or completed prior to randomization. In the absence of national guidelines, the following has been demonstrated: TB has been treated adequately by antibiotics, cure can be demonstrated and risk factors resulting in TB exposure and contracting have been removed., Elevated alanine aminotransferase (ALT) =3x ULN (if ALT at screening is >3x but <5x ULN, a re-test will be allowed. If ALT at ","PAPA syndrome;Therapeutic area: Diseases [C] - Immune System Diseases [C20]","Product Name: Placebo is solution for injection (150 mg/ml) contained in vials equal to those of Canakinumab and appears identical to the Test product. Placebo is provided by Novartis pharma., Product Code:N/A, Pharmaceutical Form: N/A, Other descriptive name: N/A , Strength: , Pharmaceutical form of the placebo: N/A , Product Name: Ilaris 150 mg/ml solution for injection, Product Code:PRD4821251, Pharmaceutical Form: SOLUTION FOR INJECTION, Other descriptive name: , Strength:",,,2021-005754-28,"Academic study; IMP donated by Novartis (Canakinumab) with a funding of 30.000 €",,Authorised,19/11/2024,,,,,,,,https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-517155-13-00,,,,,,,Yes,"Plan to produce publications on relevant national and international rheumatologic medical journals",Yes,False,"          "
CTIS2024-514306-31-00,"15 September 2025","A study to test whether spesolimab helps people with a skin condition called pyoderma gangrenosum","A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy - 1368-0140                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ",,"Boehringer Ingelheim International GmbH",29/08/2024,"  20240829","10/03/2025 17:03:09","Clinical Trials Information System",https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-514306-31-00,Recruiting,Yes,18,65+,"Female: yes Male: yes",19/03/2025,93,"Interventional clinical trial of medicinal product","Controlled: no Randomised: no Open: no Single blind: no Double blind: no Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: no Number of treatment arms in the trial:","Human pharmacology (Phase I): No Therapeutic exploratory (Phase II): No Therapeutic confirmatory - (Phase III): Yes Therapeutic use - (Phase IV): No","Japan;Taiwan;Brazil;Argentina;United States;Switzerland;Malaysia;Canada;China;Australia;Austria;Belgium;Finland;France;Germany;Italy;Portugal;Spain;Sweden;Norway;Poland","CT Disclosure & Data Transparency",,,clintriage.rdg@boehringer-ingelheim.com,+498002430127,"Boehringer Ingelheim International GmbH","Inclusion criteria: Adult trial participants, aged =18 years (if local legislation for age of consent differs, then local legislation will be followed) at screening., Signed and dated written informed consent in accordance with International Council on Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial., A confirmed diagnosis of ulcerative pyoderma gangrenosum (PG) (=10 points on the PARACELSUS score) that requires systemic therapy in the opinion of the investigator. The diagnosis needs to be confirmed by an Adjudication Committee. Trial participants with mixed PG subtypes are eligible as long as the target lesion is of the ulcerative subtype., At least one measurable (defined as measuring =5 cm2) PG ulcer. In trial participants with more than one PG ulcer, the target PG ulcer will be selected by the investigator and confirmed by external Adjudication Committee., At the time of the Screening Visit, a maximum duration of 6 months since the target ulcer in the current PG episode was diagnosed. Target ulcers >6 months since diagnosis are allowed if they are active and progressing, as judged by the investigator and confirmed by an Adjudication Committee., Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria and instructions on the duration of use is provided in the participant information and in Section 4.2.2.3 of the protocol.","Exclusion criteria: Trial participants with non-PG lesions., Trial participants with a target PG ulcer measuring >80 cm2., Trial participants with chronic, non-inflamed PG wounds or ulcers that are not responsive to immunosuppressive therapy, as determined by an Adjudication Committee., Presence of active ulcer infection at the Screening Visit (unless treated and resolved prior to administration of the first dose of trial medication) based on investigator assessment., Presence of persistent or recurring bacterial infection requiring systemic antibiotic therapy; or clinically significant viral, fungal, or parasitic infections within 2 weeks prior to the Screening Visit. Any such infection must be resolved, with treatment completed =2 weeks prior to the Screening Visit. No new/recurrent infections should have occurred prior to Visit 2., Active or latent tuberculosis (TB) • Participants with active TB are excluded • Participants with latent TB may be included if treatment of latent TB, as per local guidelines, is initiated prior to randomization and completed during the course of the trial., Chronic or acute infections including Human immunodeficiency virus (HIV) infections and viral hepatitis (including occult hepatitis); the corresponding laboratory tests will be performed during screening. A trial participant can be re-screened if the trial participant was treated and is cured from the acute infection., Severe, progressive, or uncontrolled hepatic disease, defined as >3x Upper Limit of Normal (ULN) elevation in Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) or alkaline phosphatase, or >2x ULN elevation in total bilirubin., Further exclusion criteria apply.","Pyoderma gangrenosum;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]","Product Name: , Product Code:PRD9853966, Pharmaceutical Form: SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: Placebo matching to spesolimab, Product Code:N/A, Pharmaceutical Form: N/A, Other descriptive name: N/A , Strength: , Pharmaceutical form of the placebo: N/A","Main Objective: The primary objective is to demonstrate superiority of spesolimab over placebo in the difference in the proportion of trial participants with achievement of complete closure (100% pyoderma gangrenosum (PG) area reduction, PGAR-100) of the target PG ulcer at any time up to Week 26.;Secondary Objective: Secondary objectives are to demonstrate superiority of spesolimab against placebo for the (key) secondary endpoints.;Primary end point(s): Achievement of complete closure (PGAR-100 (100% pyoderma gangrenosum area reduction)) of the target PG ulcer at any time up to Week 26 and confirmed at the next consecutive visit (at least 2 weeks later)","Secondary end point(s):Key secondary endpoint: Achievement of PGAR-100 of the target PG ulcer at Week 26 confirmed at the next consecutive visit (at least 2 weeks later);Secondary end point(s):Achievement of 50% area reduction (PGAR-50) of the target PG ulcer at any time up to Week 26;Secondary end point(s):Achievement of = 3 point reduction in NRS Pain score from baseline at Week 26;Secondary end point(s):Achievement of a DLQI of = 5 at Week 26;Secondary end point(s):Achievement of PGAR-100 of any measurable PG ulcer (=5 cm2 at baseline) at any time up to Week 26 and confirmed at the next consecutive visit (at least 2 weeks later);Secondary end point(s):Achievement of PGAR-100 of all measurable PG ulcers (=5 cm2 at baseline) at any time up to Week 26 and confirmed at the next consecutive visit (at least 2 weeks later);Secondary end point(s):Time to recurrence among trial participants who had achieved complete response (CR, complete closure of all PG ulcers) at Week 26 up to Week 52. Recurrence is defined as emergence of the disease (PG ulcer[s]) at the previous ulcer sites(s) or emergence of any new PG ulcer(s)",U1111-1306-8055,,"Boehringer Ingelheim Espana S.A.",Authorised,18/12/2024,,,,,,,,https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-514306-31-00,,,,,,,Yes,"Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed “Document Sharing Agreement”. Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined on the website.Time Frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.Access Criteria: For study documents – upon signing of a ‚Document Sharing Agreement‘.For study data – 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.",Yes,"True ","parent    "
NCT06563323,"2 September 2024","Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)","A Single-arm Open-label Study Assessing Short-term (Week 6, 16) and Long-term (Week 32) Efficacy of Guselkumab in Adult Participants With Pyoderma Gangrenosum",GEORGE,"Oregon Health and Science University",07/08/2024,"  20240807","10/03/2025 17:03:09",ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT06563323,"Not recruiting",No,"18 Years","99 Years",All,01/01/2025,17,Interventional,"Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2","United States"," ; ; ","Alex G Ortega-Loayza, MD, MCR;Alex G Ortega-Loayza, MD, MCR;Alex Ortega, MD, MCR",,;ortegalo@ohsu.edu;ortegalo@ohsu.edu,;503-418-3376;503-418-3376,"Oregon Health and Science University, Department of Dermatology;","Inclusion Criteria:<br><br> - Willingness to comply with study procedures/requirements<br><br> - Capable of giving informed consent<br><br> - Diagnosis of at least one PG ulcer by clinical, histological and laboratory<br>   assessments with a minimum wound size of 4 cm2.<br><br> - Undergoing at least once a week standard of care wound care at home or at a wound<br>   care facility<br><br> - Are candidate for systemic therapy. Must be on a stable dose of prednisone of 20<br>   mg/day for at least two weeks prior to first drug administration.<br><br> - Males ages 18-99 who agree to not father a child or donate sperm while on study and<br>   at least 12 weeks following last dose of the study drug. If subject is sexually<br>   active male and could cause pregnancy, subject much be sure that female partner(s)<br>   are using birth control that works well or not have sex.<br><br> - Females ages 18-99; either of non-childbearing potential or of childbearing<br>   potential who test negative for pregnancy and agree to use at least two reliable<br>   methods of birth control or remain abstinent during the study for at least 12 weeks<br>   following the last dose of guselkumab.<br><br> - Willingness to travel to study site for all study visits or living >30 miles from<br>   study site and willing/able to participate in remote videoconferencing visits with<br>   access to a computer with internet and webcam capabilities.<br><br> - Be willing to undergo perilesional and non-lesional skin biopsy at week 0 and week<br>   32 resulting in 4 biopsies during the course of the study. Participants can choose<br>   if they are willing to provide 2 additional biopsies at week 16. Refusal to give<br>   consent for any of the optional research samples does not exclude participant from<br>   participation in the study.<br><br>Exclusion Criteria:<br><br> - Has previously received at any time any therapeutic agent directly targeted to IL-23<br>   including, but not limited to, guselkumab, risankizumab, tildrakuzumab, or<br>   mirikizumab<br><br> - Any drug treatment specifically for PG including but not limited to biologics (or<br>   biosimilar of), experimental antibodies, small molecules and oral immunosuppressives<br>   used within washout periods specified below, prior to first dose of study drug:<br><br>    1. 12 weeks for ustekinumab, ixekizumab, secukinumab, brodalumab;<br><br>    2. 8 weeks for infliximab;<br><br>    3. 6 weeks for adalimumab;<br><br>    4. 4 weeks for cyclosporine A, etanercept, inhibitors of the JAK/TYK pathway and<br>     PD4 inhibitors;<br><br>    5. 2 weeks for Calcineurin inhibitor topicals (including but not limited to<br>     pimecrolimus and tacrolimus) and other advanced topicals (including but not<br>     limited to roflumilast and tapinarof).<br><br>If not specified specifically, a time of 4 weeks or 5 half-lives of the drug (whichever<br>is longer) prior to first drug administration.<br><br> - Intralesional corticosteroids within 4 weeks of screening.<br><br> - Active clinically infected ulcers. Individuals will be eligible for enrollment<br>   following completed treatment and resolution of infection. Antibiotics for wound<br>   superinfection are allowed.<br><br> - Immunomodulating medications for managing underlying comorbidities associated with<br>   PG, but not PG itself (e.g., for irritable bowel disease (IBD) or rheumatoid<br>   arthritis), are allowed as combination therapy except for Methotrexate (MTX) and<br>   Leflunomide which are allowed individually but not in combination.<br><br> - Concurrent skin disease that is deemed to interfere with assessment of ulcer.<br><br> - Have signs or symptoms suggestive of possible lymphoproliferative disease, including<br>   lymphadenopathy or splenomegaly or a history of lymphoproliferative disease within 5<br>   years before screening; or currently has a known malignancy or has a history of<br>   malignancy within 5 years before screening, with the exception of a nonmelanoma skin<br>   cancer that has been adequately treated with no evidence of recurrence for at least<br>   3 months before the first study drug administration or cervical carcinoma in situ<br>   that has been treated with no evidence of recurrence for at least 3 months before<br>   the first study drug administration.<br><br> - Recent (within past 6 months) cerebrovascular accident, myocardial infarction,<br>   coronary stenting. Uncontrolled hypertension - confirmed systolic blood pressure<br>   >160 mmHg or diastolic blood pressure >100 mm Hg.<br><br> - Clinically significant (per investigator's judgement) drug or alcohol abuse within<br>   the last 6 months preceding the Baseline Visit.<br><br> - Has not fully recovered from major surgery (e.g., requiring general anesthesia and<br>   hospitalization) within 8 weeks before screening, or has such surgery planned during<br>   the time the participant is expected to participate in the study (40 weeks) which in<br>   the opinion of the investigator would pose an unacceptable risk to the subject.<br><br> - Presence of significant uncontrolled respiratory, hepatic, renal, endocrine,<br>   hematologic, neurologic, or neuropsychiatric disorders, or abnormal laboratory<br>   screening values that, in the opinion of the investigator, pose an unacceptable risk<br>   to the subject if participating in the study or of interfering with the<br>   interpretation of the data.<br><br> - Have clinical laboratory test results at screening that are outside the normal<br>   reference range of the population and are considered clinically significant, or have<br>   any of the following specific abnormalities: Neutrophil count <1500 cells/µL,<br>   Lymphocyte count <500 cells/µL, Platelet count <100,000 cells/µL, AST or ALT or<br>   alkaline phosphatase > 2 times the upper limit of normal, Hemoglobin <10 g/dL, Serum<br>   creatinine =1.5 mg/dL (SI: =137 µmol/L), White blood cells <3500 cells/ µL<br><br> - Participant has known allergies, hypersensitivity, or intolerance to guselkumab or<br>   its excipients.<br><br> - Individuals who are pregnant, lactating or breastfeeding.<br><br> - History of chronic or recurrent infections, or active, untreated, acute infection,<br>   or immunocompromised to an extent that participation in the study would pose an<br>   unacceptable risk to the subject based on the investigator's clinical assessment.<br><br> - Clinically serious infection or received intravenous antibiotics for an infection,<br>   within 8 weeks before first dose.<br><br> - Have signs or symptoms suggestive of active Tuberculosis (TB) upon medical history<br>   and/or physical examination. An exception is made for participants who are currently<br>   receiving treatment or will initiate treatment for latent TB prior to first<br>   administration of study intervention. For participants with a history of treated<br>   latent TB there must be documentation of appropriate treatment prior to the first<br>   administration of study intervention.<br><br> - Positive for human immunodeficiency virus (HIV), active hepatitis B virus, or<br>   hepatitis C virus. A positive Hepatitis B surface antibody test with a corresponding<br>   negative hepatitis B surface antigen test indicates immunity to the disease and will<br>   not be exclusionary.<br><br> - Symptomatic herpes zoster infection within 12 weeks of screening or recurrent or<br>   disseminated (even a single episode) herpes zoster.<br><br> - Symptomatic herpes simplex or disseminated (even a single episode) herpes simplex at<br>   the Week 0 (baseline) visit.<br><br> - History of disseminated opportunistic ",,"Pyoderma Gangrenosum;Skin Diseases;Wound Heal;Pyoderma;Skin Ulcer","Drug: Guselkumab",Healing,"Physician Global Assessment (PGA);Decrease in ulcer area size long-term;Decrease in ulcer area size short-term;Mean decrease in ulcer area size short-term;Mean decrease in ulcer area size long-term;Skindex Mini;Skin pain scale improvement over 7 days;Skin pain scale improvement over 24 hours;Change in physical function;Mean change in global assessment score;Target ulcer remains healed;Time to recurrence;Treatment failure","Guselkumab for treatment of PG","Please refer to primary and secondary sponsors","Janssen Scientific Affairs, LLC;Ohio State University",,,,,,,,,,,,,,,,,,,Yes,False,"          "
NCT06092216,"22 September 2025","Spesolimab in Pyoderma Gangrenosum","Characterizing Pyoderma Gangrenosum Lesion Regression and Remission by IL-36 Receptor Targeting With Spesolimab",,"Icahn School of Medicine at Mount Sinai",16/10/2023,"  20231016","10/03/2025 17:03:09",ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT06092216,"Not recruiting",No,"18 Years",N/A,All,23/09/2023,5,Interventional,"Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2","United States"," ","Saakshi Khattri, MD",,,,"Icahn School of Medicine at Mount Sinai","Inclusion Criteria:<br><br> - Male or female subjects = 18 years of age at the time of signing the informed<br>   consent document<br><br> - Subject is able to understand and voluntarily sign an informed consent document<br>   prior to participation in any study assessments or procedures<br><br> - Subject is able to adhere to the study visit schedule and other protocol<br>   requirements.<br><br> - Subject has clinically diagnosed ulcerative PG with PARACELSUS score greater than or<br>   equal to 10<br><br> - Subject has at least one clinically measurable ulcerative PG lesion on body that has<br>   failed to respond to at least one prior therapy such as (but not limited to) topical<br>   corticosteroids, intralesional triamcinolone, prednisone, cyclosporine, IL-23<br>   inhibitor, IL-17 inhibitors, IL-1 inhibitors, or TNF-a- blocker therapy<br><br> - Subject has moderate to severe PG as determined by a GPG severity score of =3<br><br> - Subject is judged to be in otherwise good overall health as judged by the<br>   investigator, based on medical history, limited physical examination, and laboratory<br>   testing. (NOTE: The definition of good health means a subject does not have<br>   uncontrolled significant co-morbid conditions).<br><br> - Females of childbearing potential (FCBP) must have a negative pregnancy test at<br>   Screening and Baseline. While on investigational product and for at least 28 days<br>   after taking the last dose of investigational product, FCBP who engage in activity<br>   in which conception is possible must use one of the approved contraceptive options<br>   described below:<br><br>    - Option 1: Any one of the following highly effective contraceptive methods:<br>     hormonal contraception (oral, injection, implant, transdermal patch, vaginal<br>     ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy.<br><br>    - Or option 2: Male or female condom (latex condom or nonlatex condom NOT made<br>     out of natural [animal] membrane [for example, polyurethane]). PLUS one<br>     additional barrier method:<br><br>      - (a) diaphragm with spermicide<br><br>      - (b) cervical cap with spermicide;<br><br>      - or (c) contraceptive sponge with spermicide.<br><br>The female subject's chosen form of contraception must be effective by the time the<br>female subject presents for her Baseline visit (for example, hormonal contraception<br>should be initiated at least 28 days before first spesolimab infusion at Baseline).<br><br>Exclusion Criteria:<br><br> - Subject has a persistent or recurring bacterial infection requiring systemic<br>   antibiotics, or clinically significant viral or fungal or helminth parasitic<br>   infections, within 2 weeks of the Screening Visit. Any treatment of such infections<br>   must have been completed at least 2 weeks prior to the Screening Visit and no<br>   new/recurrent infections should have occurred prior to the Baseline Visit.<br><br> - Subject with current or history of positive human immunodeficiency virus (HIV), or<br>   congenital or acquired immunodeficiency (i.e. Common Variable Immunodeficiency<br>   [CVID]), hepatitis B or C, or active or untreated latent tuberculosis.<br><br> - Subject has clinically significant (as determined by the investigator) renal,<br>   hepatic, hematologic, intestinal, endocrine, pulmonary, cardiovascular,<br>   neurological, psychiatric, immunologic, or other major uncontrolled diseases that<br>   will affect the health of the subject during the study, or interfere with the<br>   interpretation of study results. Uncontrolled disease defined as hospitalization<br>   within 1 month of screening visit or determined by specialist (rheumatologist,<br>   gastroenterologist) consulted prior to study start.<br><br> - Subject has presence of acute demyelinating neuropathy<br><br> - Major surgery (according to the investigator's assessment) performed within 12 weeks<br>   prior to receiving first dose of spesolimab or planned during trial such as hip<br>   replacement, aneurysm removal, stomach ligation, or otherwise determined by<br>   investigator<br><br> - Subject has a suspected or active lymphoproliferative disorder or malignancy<br><br> - Subject was treated previously with spesolimab or another IL-36R inhibitor biologic<br><br> - Any documented active or suspected malignancy or history of malignancy within 5<br>   years prior to screening, except appropriately treatment basal or squamous cell<br>   carcinoma of the skin or in situ carcinoma of uterine cervix.<br><br> - Subject has received a live attenuated vaccine = 30 days prior to study initiation.<br><br> - History of adverse systemic or allergic reactions to any component of the study<br>   drug.<br><br> - Female subject who is pregnant or breast feeding",,"Pyoderma Gangrenosum","Drug: Spesolimab","Change in Global Pyoderma Gangrenosum (GPG) Severity Score","Number of participants with Complete re-epithelization of PG lesions;Absolute Change in patient-reported Pain severity (Pain-VAS) score;Absolute Change in Dermatology Life Quality Index (DLQI);Recurrence of PG lesions (GPG >0) after achieving complete re-epithelialization (GPG score 0) and spesolimab cessation;Severity of the recurrence of PG lesions - Global Pyoderma Gangrenosum (GPG) Severity Score",STUDY-23-00611,"Please refer to primary and secondary sponsors","Boehringer Ingelheim",,,,,,,,,,,,,,,,,,,No,False,"          "
NCT05984654,"8 September 2025","Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum","A Prospective, Open-label, Randomized, Split-ulcer Trial to Evaluate the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Chronic Pyoderma Gangrenosum.",,"Ohio State University",02/08/2023,"  20230802","10/03/2025 17:03:09",ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05984654,"Not recruiting",No,"18 Years",N/A,All,28/05/2024,0,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ",N/A,"United States"," ","Benjamin H. Kaffenberger, MD",,,,"The Ohio State University- Dermatology","Inclusion Criteria:<br><br> 1. Have given written informed consent before participating in any study-specific<br>   activity.<br><br> 2. Have a clinical diagnosis of classic PG as determined by the principal investigator<br>   based on results from clinical, histological, and laboratory assessments.<br><br> 3. Have at least 2 PG ulcer characterized by 'item a' AND 3/5 features in 'item b' OR<br>   2/5 features in 'item b' with support from one of the conditions listed in c. a.<br>   Stable or increasing size within 2 months preceding screening by patient report or<br>   documentation. b. Features such as violaceous border, undermining, cribriform<br>   scarring, pustules, peristomal location. c. Identifiable secondary systemic<br>   condition, such as IBD, arthritis, MGUS, noncancerous hematologic disease,<br>   streptococcal carriage, levamisole-tainted cocaine, Bruton's agammaglobulinemia.<br><br> 4. Have at least two PG target ulcers that have an area = 2 cm2 and = 200 cm2 at<br>   screening.<br><br> 5. Age at least 18 years at screening.<br><br> 6. A negative pregnancy test (for females of childbearing potential) at both screening<br>   and at Day 0.<br><br> 7. PARACELSUS Score for pyoderma gangrenosum of 10 or greater.<br><br>Exclusion Criteria:<br><br> 1. Any condition (e.g., psychiatric illness, severe alcoholism, or drug abuse) or<br>   situation that may compromise the ability of the subject to give written informed<br>   consent, may put the subject at significant risk, may jeopardize the subject's<br>   safety after treatment, may confound the study results, or may interfere<br>   significantly with the subject's participation in the study.<br><br> 2. History of malignancy within 2 years of screening other than carcinoma in situ of<br>   the cervix or adequately treated, non-metastatic, squamous, or basal cell carcinoma<br>   of the skin.<br><br> 3. History of seropositivity for HIV antibody; active or carrier status of hepatitis B<br>   [surface antigen (HBsAg) positive, or core antibody (anti-HBc) positive with<br>   negative surface antibody]; active hepatitis C (i.e., not treated or not cleared<br>   spontaneously, as confirmed by HCV PCR).<br><br> 4. Patients with hemodynamic instability, bleeding disorders, and/or platelet<br>   dysfunction syndrome.<br><br> 5. A complete blood count will be performed for each participant at the beginning of<br>   the study and those with serum hemoglobin concentration <11 g/ dL or hematocrit <34%<br>   or platelet count<1, 00000/ml will be excluded from the study.<br><br> 6. Patients with uncontrolled secondary systemic disease in the opinion of the<br>   investigator.<br><br> 7. Systemic infection or active local infection requiring oral antibiotics within 2<br>   weeks of Day 0.<br><br> 8. History of the following treatments:<br><br>    1. Patients taking anticoagulant medication.<br><br>    2. Changes (addition, discontinuation, or changes in dose) in immunosuppressive<br>     medication (including cyclosporine, azathioprine, methotrexate, mycophenolate<br>     mofetil, apremilast, dapsone, or corticosteroids) and biologics (Anti-TNF or<br>     other biologic therapies) within 2 months of Day 0.<br><br>    3. Systemic corticosteroids > 20 mg per day (prednisone or prednisone equivalent)<br>     within 8 weeks of Day 0 or change in dose within 4 weeks of Day 0. Steroids may<br>     be tapered (although not increased above the Day 0 dose) during the trial as<br>     determined by the principal investigator.<br><br>    4. Intralesional corticosteroids within 8 weeks of day 0; topical immunomodulators<br>     are also not permitted.<br><br>    5. Systemic antibiotics within 2 weeks of Day 0.<br><br>    6. Hyperbaric treatment within 4 weeks of Day 0.<br><br>    7. Investigational drug or investigational device within 4 weeks of Day 0.<br><br>    8. Other treatments not described above should be maintained at a stable dose and<br>     frequency throughout the study as best as possible.<br><br> 9. Major, general surgery within 3 months of screening, or anticipated general surgery<br>   during the study period.<br><br> 10. Pregnancy plans to become pregnant during the study, delivery within 3 months of<br>   screening, or breastfeeding.<br><br> 11. If previous use of cyclosporine or systemic corticosteroids, failure to have any<br>   stabilization/response is exclusionary. This potentially indicates the disease is<br>   not PG.",,"Pyoderma Gangrenosum","Procedure: Platelet rich plasma therapy","Proportion of ulcers with complete healing or 50 % area reduction","Total surface area change;Patient Global Assessment (PGA) change;Investigator Global Assessment (IGA) change;Patient pain perception;Change in quality of life",2023H0207,"Please refer to primary and secondary sponsors",,,,,,,,,,,,,,,,,,,,Yes,False,"          "
NCT05964413,"8 September 2025","Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum","A Randomized, Double-blind, Placebo-controlled, Multicenter, Adaptive Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in the Treatment of Ulcerative Pyoderma Gangrenosum",,"InflaRx GmbH",29/06/2023,"  20230629","10/03/2025 17:03:09",ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05964413,"Not recruiting",Yes,"18 Years",N/A,All,01/11/2023,90,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). ","Phase 3","United States;Australia;Belgium;France;Germany;Hungary;Italy;Poland;Spain;Switzerland;Australia;Belgium;France;Germany;Hungary;Italy;Poland;Spain;Switzerland;United States"," ","Alex GO Loayza, Prof, MD",,,,university,"Main Inclusion Criteria:<br><br> 1. 18 years or older at the time of signing the informed consent.<br><br> 2. Investigator confirmed clinical diagnosis of ulcerative PG. Diagnosis shall be<br>   supported by clinical assessment of PG symptoms via PARACELSUS score (Jockenhofer,<br>   Wollina et al. 2019) of 10 points or more (see Appendix - Section 12.1). Note: in<br>   case of PARACELSUS score < 10, additional justification shall be provided by the<br>   investigator to support clinical diagnosis of ulcerative PG.<br><br> 3. Minimum of 1 evaluable PG ulcer (other than peristomal) which qualifies as the<br>   target ulcer by meeting the following criteria (Orfaly, Reese et al. 2022): area of<br>   = 5 cm 2 at screening and baseline<br><br>    - circulated by intact skin<br><br>    - evaluable by at least 2-dimensional measurement<br><br>Main Exclusion Criteria:<br><br> 1. Patients with target ulcers exceeding 80 cm 2 .<br><br> 2. Patients with target ulcer in transplanted skin.<br><br> 3. Surgical wound debridement or negative pressure wound therapy (NPWT) for the target<br>   ulcer within 4 weeks before baseline (i.e., start of treatment with IMP).<br><br> 4. Patient with previous exposure to vilobelimab (IFX-1) prior to baseline (i.e., start<br>   of treatment with IMP).<br><br> 5. Patient receives/has received a vaccine within 2 weeks prior to baseline (i.e.,<br>   start of treatment with IMP).<br><br> 6. Any active infection requiring systemic antibiotic or other systemic treatment or<br>   suppressive anti-infective therapy within 2 weeks prior to baseline (i.e., start of<br>   treatment with IMP).<br><br> 7. Patients received any systemic medical treatment for PG within 4 weeks prior to<br>   baseline<br><br> 8. Patients received any biological or immunomodulatory therapy for PG within 4 weeks<br>   prior to baseline (i.e., start of treatment with IMP), except existing biologic or<br>   immunomodulatory therapy used for an underlying disease (other than PG at a stable<br>   therapy with no dose adjustments for at least two maintenance doses prior to<br>   screening this is allowed to be continued.<br><br> 9. Patients receiving corticosteroids treatment for PG of more than 10 mg/day of<br>   prednisone or equivalent within 4 weeks prior to baseline (i.e., start of treatment<br>   with IMP).",,"Pyoderma Gangrenosum","Drug: vilobelimab;Drug: Placebo","Efficacy of treatment with vilobelimab compared to placebo","Efficacy of treatment with vilobelimab compared to placebo;Pain reduction",IFX-1-P3.4,"Please refer to primary and secondary sponsors",,,,,,,,,,,,,,,,,,,,Yes,"True ","parent    "
NCT05821374,"8 September 2025","Deucravacitinib in PG","Novel Treatment of Pyoderma Gangrenosum With Deucravacitinib",,"Dartmouth-Hitchcock Medical Center",20/03/2023,"  20230320","10/03/2025 17:03:09",ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT05821374,"Not recruiting",No,"18 Years","70 Years",All,29/04/2024,0,Interventional,"Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Early Phase 1","United States"," ","Brian J. Simmons, MD",,,,"Dartmouth-Hitchcock Medical Center","Inclusion Criteria:<br><br> - Men and women between the ages of 18-70 years old<br><br> - Diagnosed with pyoderma gangrenosum requiring one major and at least 4 minor<br>   criteria<br><br> - Women must not be pregnant, lactating, or planning pregnancy during the study period<br><br> - Women of child-bearing potential must be on birth control for the duration of the<br>   treatment period.<br><br> - Subjects must agree to the use of at least one of the following contraception<br>   methods for the entire duration of the study until at least 30 days after taking<br>   their last dose of study drug:<br><br> - Women: Hormonal contraception (oral, injections, patch, implant, or vaginal-ring);<br>   Spiral (with or without hormones); any sterilization methods; a partner who has had<br>   a vasectomy; or sexual abstinence.<br><br> - Other acceptable methods of contraception are male or female condoms (with or<br>   without spermicide) or a cap, diaphragm, or sponge with spermicide.<br><br> - Willing to discontinue topical and/or systemic therapies, with the exception of oral<br>   rescue therapy with steroids.<br><br> - The wash period for systemic therapies will largely depend on the specific treatment<br>   but, in general, will be at least 6 months for biologics and 3 months for other<br>   immune- suppressants such as cyclosporine, mycophenolate mofetil, methotrexate, etc.<br>   No wash out period is required for topicals.<br><br> - Capable and willing to sign Institutional Review Board/IEC-approved written informed<br>   consent form in accordance with regulatory and institutional guidelines before the<br>   performance of any protocol-related procedures.<br><br>Exclusion Criteria:<br><br> - Patient under 18 years of age.<br><br> - Patients with a history of inflammatory bowel disease.<br><br> - Patients on systemic immunosuppressive/immune modulating therapy including: oral<br>   steroids, cyclosporine, mycophenolate mofetil, methotrexate, Azathioprine or TNFa<br>   inhibitor at time of starting deucravacitinib.<br><br> - Patients currently enrolled in another investigational study.<br><br> - Patients with a history or evidence of active infection and/or febrile illness<br>   within 7 days; or serious infection requiring antibiotic treatment within 30 days<br><br> - Hepatitis C virus (HCV): subjects known to be positive for anti-HCV antibody or for<br>   HCV RNA detectable by polymerase chain reaction (PCR)<br><br> - Hepatitis B virus (HBV): subjects known to be positive for hepatitis B surface<br>   antigen or for HBV DNA detectable by PCR<br><br> - Human Immunodeficiency Virus (HIV) infection: subjects known to be HIV positive<br><br> - History of active or inadequately treated latent tuberculosis (TB)<br><br> - Known or suspected systemic or skin autoimmune disorder other than pyoderma<br>   gangrenosum<br><br> - Any unstable major illness or evidence of unstable condition of major organ systems<br>   including psychiatric<br><br> - Cancer or history of lymphoproliferative disease within last 5 years; exception is<br>   cutaneous basal cell carcinoma or squamous cell carcinoma that has been treated.<br><br> - Major surgery within the last 4 weeks<br><br> - Live vaccines within the last 60 days<br><br> - Leukopenia (absolute WBC count < 3000/mm3); Lymphopenia (ALC < 500/mm3); Neutropenia<br>   (ANC < 1000/mm3)<br><br> - Thrombocytopenia (platelet count < 100,000/mm3; Anemia (hemoglobin < 9.0g/dL)<br><br> - ALT/AST > 3 X ULN and/or Total, unconjugated, and/or conjugated bilirubin > 2 X ULN<br>   within 28 days of dosing",,"Pyoderma Gangrenosum","Drug: Deucravacitinib","Change in Physician's Global Assessment (PGA);Change from baseline in ulcer size measured by calculating the area of the ulcers in centimeters squared using a digital application.","The percentage of patients needing rescue therapy from baseline to Day 115",STUDY02001753,"Please refer to primary and secondary sponsors","Bristol-Myers Squibb",,,,,,,,,,,,,,,,,,,Yes,False,"          "
ACTRN12623000211662,"18 September 2023","A Biomarker-Driven Approach to Identify Pathogenic Mechanisms and Novel Therapeutic Targets in Chronic Wounds (Pyoderma Gangrenosum) using Tildrakizumab","A Biomarker-Driven Approach to Identify Pathogenic Mechanisms and Novel Therapeutic Targets in Chronic Wounds (Pyoderma Gangrenosum) using Tildrakizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ",,"Liverpool Hospital",28/02/2023,"  20230228","10/03/2025 17:03:09",ANZCTR,https://anzctr.org.au/ACTRN12623000211662.aspx,"Not Recruiting",No,"18 Years","99 Years","Both males and females",02/03/2023,10,Interventional,"Purpose: Treatment; Allocation: Non-randomised trial;","Phase 2",Australia,"Dr John Frew",,"Department of Dermatology,Liverpool Hospital Suite 7, Level 1, 45-47 Goulburn St Liverpool NSW 2170",john.frew@unsw.edu.au,"+61 2 87384560",,"Inclusion criteria: • Age greater than or equal to 18 years<br>• A minimum of one (1) active ulcer of Pyoderma Gangrenosum as determined by the PI<br> ","Exclusion criteria: Women lactating, pregnant or of childbearing potential who are not willing to avoid becoming pregnant during the study.<br>• Individuals with concurrent use of systemic antibiotics/ oral retinoids/ systemic immunosuppressants (those with prior use of these medications must have conducted a washout period of 4 weeks or 5 half-lives of the drug, whichever is longer).<br>• Any medical, psychological or social condition that, in the opinion of the Investigator, would jeopardize the health or well-being of the participant during any study procedures or the integrity of the data.<br>• Have received a vaccination with a live viral of bacterial component within 4 weeks or less of intended Tildrakizumab administration<br>• Patients not willing to abstain from receiving live vaccinations during treatment and for at least 17 weeks after treatment","Pyoderma Gangrenosum; <br>Pyoderma Gangrenosum;Inflammatory and Immune System - Other inflammatory or immune system disorders;Skin - Dermatological conditions","Tildrakizumab 200mg subcutaneous injection every 4 weeks, given via supervised injection in clinic for a total of 12 weeks.","Alterations in Gene Expression Profiling, cell counts (CD3+, CD11c+, Neutrophil Elastase+, CD20+, CD138+) at Week 12 compared to Baseline (composite primary outcome) using skin biopsy[ Week 12 post-first dose]","Safety and Tolerability (Grade 2/3 Adverse Effects); examples of known events include injection site reactions, upper respiratory tract infections. These will be assessed by history taking and clinical examination.[ Week 12 post first dose];Changes in Disease Activity (Measures by size of ulcer and global assessment VAS) using analysis of digital photographs[ Week 12 post first dose]","Nil Known","Sun Pharma",,Approved,26/10/2021,"South Western Sydney Local Health District ","Elizabeth St Liverpool NSW 2170",,,Yes,13/09/2023,,,10/08/2023,,,,,,No,,Yes,False,"          "
EUCTR2021-005754-28-IT,"16 December 2024","A double-blind, placebo-controlled, randomized withdrawal study of canakinumab in pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome","A double-blind, placebo-controlled, randomized withdrawal study of canakinumab in pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome - PAPA-Can study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ",,"IRCCS ISTITUTO GIANNINA GASLINI",31/01/2023,"  20230131","10/03/2025 17:03:09","EU Clinical Trials Register",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-005754-28,"Not Recruiting",Yes,,,"<br>Female: yes<br>Male: yes<br>",10/07/2023,24,"Interventional clinical trial of medicinal product","Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: no Number of treatment arms in the trial: 2 ","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
",Italy,"Mal. Autoinf. e Immunodeficienze",,"Via Gaslini, 5",printo@gaslini.org,+390104211018,"IRCCS Istituto Giannina Gaslini","Inclusion criteria: <br>1. Clinical diagnosis of PAPA with active flare at the time of enrolment.<br>2. Mutation of the PSTPIP1 gene.<br>Are the trial subjects under 18? yes<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 10<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 2<br>","Exclusion criteria: <br>1.Use of the following therapies:<br>a.Corticosteroids (prednisone equivalent > 0.2 mg/kg/day [or greater than the maximum of 15 mg/ day for children over 60 kg]) within 1 week prior to Baseline<br>b.Anakinra within 72 hours prior to Baseline<br>c.Other biologics (including Canakinumab) or immunosuprassant 2 half-life prior to Baseline. <br>2.Any conditions or significant medical problems which in the opinion of the investigator immunocompromises the patient and/ or places the patient at unacceptable risk for immunomodulatory therapy<br>3.Live vaccinations within 3 months prior to the start of the trial, during the trial, and up to 3 months following the last dose<br>4. Pregnant or nursing women<br>5.Female adolescents (=18 years of age) of childbearing potential who do not agree to abstinence or, if sexually active, do not agree to the use of contraception .<br>","PAPA syndrome (Pyogenic Arthritis, Pyoderma gangrenosum and Acne) <br>MedDRA version: 20.0Level: LLTClassification code 10072225Term: PAPA syndromeSystem Organ Class: 100000004850 <br>MedDRA version: 20.0Level: LLTClassification code 10072225Term: PAPA syndromeSystem Organ Class: 100000004850 <br>MedDRA version: 20.0Level: LLTClassification code 10072225Term: PAPA syndromeSystem Organ Class: 100000004850 <br>MedDRA version: 20.0Level: LLTClassification code 10072225Term: PAPA syndromeSystem Organ Class: 100000004850;Therapeutic area: Diseases [C] - Immune System Diseases [C20]","<br>Product Name: Canakinumab<br>Product Code: [Canakinumab]<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: CANAKINUMAB<br>CAS Number: 914613-48-2<br>Current Sponsor code: ilaris, Canakinumab<br>Concentration unit: mg milligram(s)<br>Concentration type: up to<br>Concentration number: 450-<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Subcutaneous use<br><br>","Main Objective: To determine whether canakinumab administered every 4 weeks is able to maintain disease remission compared to placebo in canakinumab-responder patients;Secondary Objective: 1)To determine the efficacy of canakinumab to achieve a complete or almost complete response after 24 weeks <br>2)To evaluate optimal dose of canakinumab to induce disease remission<br>3)To assess the profile over time in each of the 4 key PAPA signs and symptoms (arthritis, foruncolosis, pyoderma gangrenosum, hydrosiadenite suppurativa) from baseline to end of study. <br>4)To assess the profile over time in physician’s and patients’s global assessment score from baseline to end of study.<br>5)To assess the profile over time in acute phase reactants (ESR, CRP, SAA) from baseline to end of study.;Primary end point(s): Proportion of patients not experiencing a disease flare in the treatment arm compared to the placebo arm at week 48.;Timepoint(s) of evaluation of this end point: 48 Weeks",,PAPA-Can,Novartis,,Approved,17/04/2023,,,,,,,,,,,,"No results available","No results available","No results available",,,Yes,"True ","parent    "
NL-OMON53965,"9 April 2024","Hyperbaric Oxygen Therapy for Pyoderma gangrenosum As a New Treatment Strategy","Hyperbaric Oxygen Therapy for Pyoderma gangrenosum As a New Treatment Strategy - HOT PANTS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ",,"Erasmus MC, Universitair Medisch Centrum Rotterdam",13/07/2022,"  20220713","10/03/2025 17:03:09",NL-OMON,https://onderzoekmetmensen.nl/en/trial/53965,Recruiting,No,18,99,,13/03/2023,30,Interventional,"Non-randomized controlled trial, Open (masking not used), Other, Treatment",3,Netherlands,,,"Dr.Molewaterplein 40",,,"Erasmus MC, Universitair Medisch Centrum Rotterdam","Inclusion criteria: <p>• - Confirmed consensus on the diagnosis pyoderma gangrenosum by referring <br>specialist, principal and coordinating investigator (dermatologist, clinical <br>immunologist or rheumatologist based on PARACELSUS and Delphi score).<br>- Unsatisfactory response after six weeks of combined standard wound care and <br>systemic prednisone and/or other anti-inflammatory therapy.<br>- Fit for hyperbaric oxygen therapy as assessed by the hyperbaric physician.<br>- Age >=18 years at baseline<br>- All genders <br>- Able and willing to give written informed consent and to comply with the <br>study requirements.</p><br>","Exclusion criteria: <p>• Language barrier<br>• Unable to give informed consent <br>- Pregnancy</p><br>"," <br>Pyoderma gangrenosum; dermatitis ulcerosa;10027665;10040790","<p>30 sessions of HBO therapy at 2.4-2.5 atmosphere absolute in addition to <br>treatment conform clinical practice. Controls will be treated according to <br>clinical practice.</p><br>","<p>To assess the clinical effectiveness in wound healing time (full<br /><br>re-epithelialization) and to confirm the hypothesis the feasibility and<br /><br>possible efficacy of hyperbaric oxygen therapy in patients with pyoderma<br /><br>gangrenosum refractory to standard prednisone therapy.</p><br>","<p>- Changes in markers of inflammation, mRNA expression in micro-biopsies in<br /><br>wound edges.<br /><br>- Alterations in mitochondrial O2 levels<br /><br>- The number of activated neutrophils in peripheral venous blood.<br /><br>- To assess the effect of HBOT on Pain reduction (NRS score).<br /><br>- To assess the effect of HBOT on Health Related-Quality of Life (WOUND-Q).<br /><br>- To assess the prevalence of recurrence of PG in patients treated with and<br /><br>without adjuvant HBOT.</p><br>",EUCTR2021-006013-11-NL;NL80793.078.22,"Ministerie van OC&W",,Approved;Approved;Approved;Approved,13/07/2022;29/08/2022;21/04/2023;05/05/2023,;;;,;;;,;;;,;;;,,,,,,,,,,,,,Yes,False,"          "
NCT05343754,"30 September 2024","Hyperbaric Oxygen Therapy for Pyoderma Gangrenosum","Hyperbaric Oxygen Therapy for Pyoderma Gangrenosum As a New Treatment Strategy",HOTPANTS,"Erasmus Medical Center",11/04/2022,"  20220411","10/03/2025 17:03:09",ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT05343754,"Not recruiting",No,"18 Years",N/A,All,01/06/2022,3,Interventional,"Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 3",Netherlands," ","Errol Prens, Prof.Dr.",,,,"Erasmus MC, dermatology department","Inclusion Criteria: -     - Confirmed consensus on the diagnosis pyoderma gangrenosum by referring     specialist, principal and coordinating investigator (dermatologist, clinical     immunologist or rheumatologist based on PARACELSUS and Delphi score). - Unsatisfactory response after six weeks of combined standard wound care and systemic   prednisone and/or other anti-inflammatory therapy. - Fit for hyperbaric oxygen therapy as assessed by the hyperbaric physician. - Age =18 years at baseline - All genders - Able and willing to give written informed consent and to comply with the study   requirements.Exclusion Criteria: -     - Language barrier - Unable to give informed consent or to comply with the trial protocol - Pregnancy",,"Pyoderma Gangrenosum","Drug: Hyperbaric oxygen;Other: Control group","Wound healing time","Cytokines changes;mitochondrial O2 levels;Neutrophil count in peripheral venous blood;pain dairy;quality of life measurement","NL 2021-006013-11","Please refer to primary and secondary sponsors",,,,,,,,,,,,,,,,,,,,Yes,False,"          "
NCT05120726,"3 June 2024","A Novel Therapeutic Treatment of Pyoderma Gangrenosum","A Novel Therapeutic Treatment of Pyoderma Gangrenosum",,"Louisiana State University Health Sciences Center in New Orleans",11/09/2021,"  20210911","10/03/2025 17:03:09",ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT05120726,Recruiting,No,"18 Years",N/A,All,02/06/2021,20,Interventional,"Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 4","United States"," ; ","Alison Smith, MD, PhD;Alison Smith, MD, PhD",,;asmi60@lsuhsc.edu,;504-903-9009,"Louisiana State University Health Sciences Center - New Orleans;","<br>    Inclusion Criteria:<br><br>     - patients diagnosed with pyoderma gangrenosum<br><br>     - patients over 18 years of age<br><br>    Exclusion Criteria:<br><br>     - members of vulnerable populations (pregnant women and prisoners)<br><br>     - patients less than 18 years of age<br>   ",,"Pyoderma Gangrenosum","Biological: Dehydrated human amnion/chorion membrane","Gene Measurements;Wound Size","Infection;Pain Level","IRB: #1579","Please refer to primary and secondary sponsors",,,,,,,,,,,,,,,,,,,,No,False,"          "
NCT04895566,"27 March 2023","Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma","Phase 0/1 Topical Application of the Monoclonal Antibody (Mab) sB24M in Patients With Severe Pyoderma",,"SWISS BIOPHARMA MED GmbH",17/05/2021,"  20210517","10/03/2025 17:03:09",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT04895566,"Not recruiting",No,"21 Years","80 Years",All,24/05/2021,10,Interventional,"Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Early Phase 1",Belarus;Latvia;Belarus;Latvia,,,,,,,"<br>    Inclusion Criteria:<br><br>     - A confirmed severe form of any type of pyoderma with lesions of the skin and muscle<br>       tissue was diagnosed<br><br>     - Male or female, age = 21 years<br><br>     - Previous treatment with TNF antagonists (infliximab, adalimumab, etanercept,<br>       certolizumab, golimumab) ended no earlier than 30 days before starting therapy<br><br>     - Secondary treatment failure with up to one previous TNFa antagonist treatment (from<br>       the list above)<br><br>     - Secondary failure of corticosteroid treatment<br><br>     - Adequate hematologic, hepatic, and renal function<br><br>     - Written informed consent.<br><br>    Exclusion Criteria:<br><br>     - History of primary resistance or intolerance to any TNFa antagonist.<br><br>     - History of congestive heart failure or current, controlled or uncontrolled<br><br>     - Women who are pregnant or breastfeeding, or women of childbearing age if no effective<br>       method of contraception has been used during and for 3 months after the trial<br><br>     - Men, if no effective contraceptive method was used during the study and for 3 months<br>       afterward<br><br>     - Any prior exposure to Hu5F9-G4 or other CD47 targeting agents<br><br>     - Previous allogeneic stem cell transplant within 6 months prior to enrollment, active<br>       graft versus host disease (GVHD), or need for graft-associated immunosuppression<br><br>     - Refusal to sign the informed consent<br>   ",,"Pyoderma;Pyoderma Gangrenosum;Pyoderma Vegetans;Pyoderma Gangrenosum Surrounding Surgical Stoma","Biological: Monoclonal antibody (Mab) sB24M","Objective response rate (ORR) in patients with severe pyoderma","Duration of response (DoR) of patients with severe forms of pyoderma",SBPM0311m,"Please refer to primary and secondary sponsors",,,,,,,,,,,,,,,,,,,,Yes,False,"          "
NCT04901325,"8 September 2025","Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)","Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)",,"Oregon Health and Science University",17/05/2021,"  20210517","10/03/2025 17:03:09",ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04901325,"Not recruiting",No,"18 Years","99 Years",All,03/10/2023,5,Interventional,"Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2","United States"," ","Alex G Ortega-Loayza, MD, MCR",,,,"Oregon Health & Science University, Department of Dermatology","Inclusion Criteria:<br><br> - Willingness to comply with study procedures/requirements<br><br> - Capable of giving informed consent<br><br> - Diagnosis of at least one PG ulcer by clinical, histological and laboratory<br>   assessments with a minimum wound size of 4 cm2.<br><br> - Male age 18-99 who agree to not father a child or donate sperm while on study and at<br>   least 1 week following last dose of the study drug. If subject is a sexually active<br>   male and could cause a pregnancy, subject must be sure that female partner(s) are<br>   using birth control that works well or not have sex.<br><br> - Female age 18-99; either of non-childbearing potential or of childbearing potential<br>   who test negative for pregnancy and agree to use at least two reliable methods of<br>   birth control or remain abstinent during the study and for at least 1 week following<br>   the last dose of baricitinib.<br><br> - Classic PG defined as deep ulceration with undermining violaceous borders.<br><br> - Are candidate for systemic therapy. All participants will be taking and clinically<br>   stable 30 mg (same ulcer size) of prednisone fort least two weeks at the start of<br>   the study. Patients must have discontinued immunosuppressive therapies<br>   (cyclosporine, azathioprine, mycophenolate mofetil, methotrexate, apremilast,<br>   dapsone) due to inadequate response or intolerance for at least 4 weeks prior to<br>   beginning the study drug.<br><br> - Undergoing at least once a week standard of care wound care at home or wound care<br>   facility.<br><br> - Willingness to travel to Oregon Health and Science University (OHSU) for all study<br>   visits, or living >30 miles from OHSU and willing/able to participate in remote<br>   videoconferencing visits with access to a computer with internet and webcam<br>   capabilities.<br><br>Exclusion Criteria:<br><br> - Have history of malignancy or lymphoproliferative disease; or have signs or symptoms<br>   suggestive of possible lymphoproliferative disease, including lymphadenopathy or<br>   splenomegaly; or have active primary or recurrent malignant disease; or have been in<br>   remission from clinically significant malignancy for < 5years.<br><br> - Patients with cervical carcinoma in situ, basal cell carcinoma or squamous cell<br>   carcinomas who have had active disease within 3 years of screening for this study.<br>   Active, untreated, acute or chronic infection (such as untreated tuberculosis), or<br>   immunocompromised to an extent that such that participation in the study would pose<br>   an unacceptable risk to the subject. (Treated infections such as latent tuberculosis<br>   after completion of the appropriate therapy are not excluded.Patients currently on<br>   treatment for active TB with drugs such as strong OAT-3 inhibitors will be excluded<br>   from study)<br><br> - Clinically serious infection or received intravenous antibiotics for an infection,<br>   within 4 weeks of randomization.<br><br> - Active viral infection that, based on the investigator's clinical assessment, makes<br>   the subject and unsuitable candidate for the study.<br><br> - Positive for human immunodeficiency virus, hepatitis B virus, or hepatitis C virus.<br><br> - Symptomatic herpes zoster infection within 12 weeks of screening or recurrent or<br>   disseminated (even a single episode) herpes zoster.<br><br> - Symptomatic herpes simplex at the time of randomization or disseminated (even a<br>   single episode) herpes simplex<br><br> - History of disseminated opportunistic infections (e.g., listeriosis and<br>   histoplasmosis).<br><br> - Have a history of venous thromboembolism (VTE), or are considered at high risk for<br>   VTE as deemed by the investigator, or have 2 or more of the following risk factors<br>   for VTE:<br><br>    1. Aged >65 years.<br><br>    2. Body mass index (BMI) >35 kg/m2.<br><br>    3. Oral contraceptive use and current smoker.<br><br> - Creatinine Clearance <30 mL/min<br><br> - Wound care debridement of any PG ulcer within 2 weeks.<br><br> - Intralesional corticosteroids within 4 weeks of screening.<br><br> - Previous exposure to a Janus kinase (JAK) inhibitor (ruxolitinib, tofacitinib,<br>   upadacitinib, filgotinib). For biologic therapies, the specific washout periods used<br>   will at least 4 weeks for anakinra, etanercept, infliximab, adalimumab, alefacept,<br>   golimumab, secukinumab, ixekizumab, risankizumab, guselkumab, tildrakizumab,<br>   canakinumab, ustekinumab and at least 24 weeks for rituximab or efalizumab.<br><br> - Patients who are currently on immunosuppressive therapies or have not discontinued<br>   them for at least 4 weeks.<br><br> - Clinically significant (per investigator's judgement) drug or alcohol abuse within<br>   the last 6 months preceding the Baseline Visit.<br><br> - Have a live vaccine within 12 weeks prior to baseline or intend to have a live<br>   vaccine during the course of study.<br><br> - Had any major surgery within 8 weeks prior to baseline or will require major surgery<br>   during the study, which in the opinion of the investigator would pose an<br>   unacceptable risk to the subject.<br><br> - Recent (within past 6 months) cerebrovascular accident, myocardial infarction,<br>   coronary stenting. Uncontrolled hypertension - confirmed systolic blood pressure<br>   >160 mmHg or diastolic blood pressure >100 mm Hg.<br><br> - Gastrointestinal (GI) perforation (other than appendicitis or penetrating injury),<br>   diverticulitis or significantly increased for GI perforation (within past 6 months)<br>   per investigator judgement; any condition could interfere with drug absorption<br>   including but not limited to short bowel syndrome.<br><br> - Presence of significant uncontrolled respiratory, hepatic, renal, endocrine,<br>   hematologic, neurologic, or neuropsychiatric disorders, or abnormal laboratory<br>   screening values that, in the opinion of the investigator, pose an unacceptable risk<br>   to the subject if participating in the study or of interfering with the<br>   interpretation of the data.<br><br> - Have clinical laboratory test results at screening that are outside the normal<br>   reference range of the population and are considered clinically significant, or have<br>   any of the following specific abnormalities: Neutrophil count <1500 cells/µL,<br>   lymphocyte count <500 cells/µL, platelet count <100,000 cells/µL, aspartate<br>   transaminase (AST) or alanine aminotransferase (ALT) > 2 times the upper limit of<br>   normal, hemoglobin <10 g/dL for male and female subjects, eGFR>60.<br><br> - Women who are lactating or breastfeeding.<br><br> - Have any other condition that precludes the subject from following and completing<br>   the protocol, in the opinion of the investigator.<br><br> - Are investigator site personnel directly affiliated with this study and/or their<br>   immediate families (spouse, parent, child, or sibling).<br><br> - Are currently enrolled in, or discontinued from a clinical trial involving an<br>   investigational product or non-approved use of a drug or device within the last 4<br>   weeks or a period of at least 5 half-lives of the last administration of the drug,<br>   whichever is longer, or concurrently enrolled in any other type of medical research<br>   judged not to be scientifically or medically compatible with this study.<br><br> - History of myocardial infarction, stroke and New York Heart Association Stage II/IV<br>   heart failure<br><br> - Patients on concomitant medication with a Strong OAT-3 inhibitor for an existing<br>   condition will be excluded fr",,"Pyoderma Gangrenosum;Skin Diseases;Wound Heal;Pyoderma;Skin Ulcer","Drug: Baricitinib",Healing,"Physician Global Assessment (PGA);Percent change in lesion surface area;Mean change in lesion surface area;Mean change in Physician Global Assessment (PGA);Sustained healing;Decrease in ulcer area size;Time to healing;Time to recurrence (weeks);Number of treatment failures;Adverse reactions to medications;Quality of life change (as measured by the Dermatology Life Quality Index);Mean change in quality of life (measured by Dermatology Life Quality Index);Skin pain scale","Baricitinib for PG Treatment","Please refer to primary and secondary sponsors",,,,,,,,,,,,,,,,,,,,Yes,False,"          "
NCT04792957,"4 April 2022","JAK-STAT Signaling Pathway in Pyoderma Gangrenosum","Expression of the JAK-STAT Signaling Pathway in Pyoderma Gangrenosum Pathological Biopsy",,"Dokuz Eylul University",08/03/2021,"  20210308","10/03/2025 17:03:09",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT04792957,"Not recruiting",No,"18 Years","90 Years",All,01/05/2022,120,Observational,,,," ","Ismail Sari, M.Sc",,ismailsari35@gmail.com,+902324122222,,"<br>    Inclusion Criteria:<br><br>     - Pyoderma gangrenosum diagnosed with skin biopsy<br><br>     - Psoriasis diagnosed with skin biopsy<br><br>     - Hidradenitis suppurativa diagnosed with skin biopsy<br><br>     - Skin biopsy in healthy subjects<br><br>    Exclusion Criteria:<br><br>    - This is a case-based study and there is no exclusion criteria<br>   ",,"Pyoderma Gangrenosum;Hidradenitis Suppurativa;Psoriasis","Diagnostic Test: immunohistochemical methods","Expression of JAK-STAT pathway",,DokuzEU-Rheumatology-1,"Please refer to primary and secondary sponsors",,,,,,,,,,,,,,,,,,,,Yes,False,"          "
NCT04750213,"8 September 2025","A Study to Assess Adverse Events and Change in Disease State in Adult Participants Being Treated With Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG)","Post-marketing Observational Study for Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG)",,AbbVie,10/02/2021,"  20210210","10/03/2025 17:03:09",ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT04750213,"Not recruiting",No,"15 Years",N/A,All,12/02/2021,60,Observational,,,Japan," ","ABBVIE INC.",,,,AbbVie,"Inclusion Criteria:<br><br> - Diagnosed with Pyoderma Gangrenosum (PG).<br><br> - Have been prescribed Humira for PG treatment within 14 days.<br><br>Exclusion Criteria:<br><br>- Have Pyoderma Gangrenosum (PG) in previous treatment with Humira.",,"Pyoderma Gangrenosum",,"Incidence Percentage of all the Infection Reported as Adverse Drug Reaction (ADR)","Incidence Percentage of Serious Infection Reported as ADR;Incidence Percentage of each ADR (Besides Infection);Change in Physician's Global Assessment (PGA) [Global] Grade;Change in PGA [Target] Grade;Change in Investigator Inflammation Assessment (IIA) Score from Start of Dosing;Change in Verbal Rating Scale (VRS) Category;Percentage of Participants with Recurrence;Time to Recurrence (Day);Percentage of PG Subtype at Recurrence;Pain Improvement Assessed with VRS",P20-251,"Please refer to primary and secondary sponsors",,,,,,,,,,,,,,,,,,,,Yes,False,"          "
EUCTR2020-003273-21-PL,"14 March 2022",NA,"Open label exploratory phase IIa trial to investigate the safety and efficacy of IFX-1 in treating subjects with Pyoderma Gangrenosum (OPTIMA). - Exploratory study of IFX-1 in Subjects with Pyoderma Gangrenosum                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ",,"InflaRx GmbH",08/09/2020,"  20200908","10/03/2025 17:03:09","EU Clinical Trials Register",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003273-21,"Not Recruiting",No,,,"<br>Female: yes<br>Male: yes<br>",09/11/2020,18,"Interventional clinical trial of medicinal product","Controlled: yes<br>Randomised: no<br>Open: yes<br>Single blind: no<br>Double blind: no<br>Parallel group: no<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: no<br>Other: yes<br>Other specify the comparator: 3 dosing groups: 800, 1600 or 2400mg<br>Number of treatment arms in the trial: 3<br>","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
","United States;Poland","Clinical Research and Development",,"Winzerlaer Strasse 2 ",info@inflarx.de,"+4989414 189 78 25","InflaRx GmbH","Inclusion criteria: <br>1.Capable of giving signed informed consent as described in Regulatory and Ethical Considerations, which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol, and approval for photographic documentation<br>2. Subjects must be 18 years or older, at the time of signing the informed consent<br>3. Male or female<br>4.Diagnosis of an ulcerative form of pyoderma gangrenosum confirmed by the investigator<br>5.In addition, the subject must fulfill at least 3 of the following 6 criteria at screening:History of<br>•Pathergy (ulcer occurring at the sites of trauma)<br>•Personal history of inflammatory bowel disease or inflammatory arthritis<br>•History of papule, pustule or vesicle that rapidly ulcerated<br>Clinical examination (or photographic evidence) of<br>•Peripheral erythema, undermining border, and tenderness at site of ulceration<br>•Multiple ulcerations<br>•Cribriform or “wrinkled paper” scar(s) at sites of healed ulcers<br>6.Subject has a minimum of 1 evaluable ulcer (=2 cm2) at screening<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 15<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 3<br>","Exclusion criteria: <br>Subjects are excluded from the study if any of the following criteria apply:<br>1.Pyoderma gangrenosum target ulcer for more than 3 years before screening<br>2.Surgical wound debridement within the previous 2 weeks before screening<br>3.Any comorbidity such as psychiatric or general illness that may put the subject at risk as determined by investigator<br>4.Poor general condition that might affect wound healing, as determined by the investigator<br>5.One of the following abnormal laboratory findings at screening:<br>•White blood cell count <3500/mm3<br>•Platelet count <100,000/mm3<br>•Hemoglobin <7 g/dL<br>•Total bilirubin >1.5 times the upper limit of normal and/or alanine aminotransferase or aspartate aminotransferase >2.5 times upper limit of normal<br>6.Human immunodeficiency virus, hepatitis B or hepatitis C viral screening test showing evidence of active or chronic viral infection at screening or a documented history of the human immunodeficiency virus, hepatitis B, or hepatitis C<br>7.Evidence of active or latent tuberculosis<br>8.History of malignancy in the previous 5 years (except for non-melanoma skin cancer and cancer in-situ of the cervix)<br>9.Subjects with ulceration due to medical causes other than pyoderma gangrenosum (e.g. diabetic ulceration)<br>10.Infection requiring suppressive anti-infective therapy (such as latent tuberculosis, pneumocystis, aspergillosis, cytomegalovirus, herpes simplex virus, herpes zoster and atypical mycobacteria)<br>11.Use of intravenous antibacterial, antiviral, anti-fungal, or anti-parasitic agents within 30 days before screening<br>12.Any drug treatment for pyoderma gangrenosum including corticosteroids (>10 mg prednisone or prednisone equivalent), intralesional steroids, cyclosporine A, biologicals and immunosuppressives (with the exception of antibiotics for wound superinfection) used within a time of 5 half-lives of the drug before screening<br>13.Received live attenuated vaccine within the previous 3 months before screening<br>14.Major surgery planned during the time of foreseen study participation<br>15.The subject has participated in an interventional clinical study during the 3 months before screening, or plans to participate in a clinical study<br>16.Previous exposure to IFX-1 in this or another study<br>17.Known hypersensitivity to polysorbate 80 (excipient of the IMP)<br>18.Prior exposure to anticomplement 5a before screening<br>19.History of sever anaphylactic reaction to any components of C5a before screening<br>20.Known or suspected active drug and/or alcohol abuse at screening<br>21.Breast feeding or pregnant woman at screening<br>22.Male and female subjects of childbearing potential unwilling to follow the contraceptive guidance in Appendix 4 during the treatment period and for at least 30 days after the last dose of IMP<br>23.Pregnancy or positive pregnancy test at screening<br>24.The subject is imprisoned or lawfully kept in an institution at screening<br>25.Evidence or suspicion that the subject might not comply with the requirements of the study protocol<br>26.The subject is an employee or direct relative of an employee at the study site or sponsor<br>27.Any other factor which, in the investigator’s opinion, is likely to compromise the subject’s ability to participate in the study<br>","Pyoderma gangrenosum <br>MedDRA version: 20.0Level: PTClassification code 10037635Term: Pyoderma gangrenosumSystem Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]","<br>Product Name: IFX-1 <br>Pharmaceutical Form: Concentrate for solution for infusion<br>CAS Number: 2250440-41-4<br>Current Sponsor code: IFX-1<br>Other descriptive name: Anti-(complement C5a) IgG4 chimeric monoclonal antibody<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br><br>Product Name: IFX-1 <br>Pharmaceutical Form: Concentrate for solution for infusion<br>CAS Number: 2250440-41-4<br>Current Sponsor code: IFX-1<br>Other descriptive name: Anti-(complement C5a) IgG4 chimeric monoclonal antibody<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br><br>","Main Objective: Explore the safety of IFX-1 for the treatment of subjects with pyoderma gangrenosum;Secondary Objective: Explore the efficacy of IFX-1 for the treatment of pyoderma gangrenosum<br>Explore additional clinical outcome parameters in subjects with pyoderma gangrenosum under the treatment with IFX-1;Primary end point(s): Occurrence, nature and intensity of treatment emergent adverse events (TEAEs), related TEAEs, serious TEAEs, and adverse events of special interest;Timepoint(s) of evaluation of this end point: Adverse Events are assessed at every visit; interim analysis and End of Trial","Secondary end point(s): Responder rate defined as Physician’s Global Assessment =3 of target ulcer at Visits V4, V6, V10, and V16 (End of Treatment [EOT])<br>Time to complete closure of pyoderma gangrenosum target ulcer (investigator assessment)<br>Percentage change in wound area and wound volume (wound healing) of target ulcer between Visits V1-V4, V1-V6, V6-V10; V10-V16, and V1-V16 (photographic assessment)<br>Rate of change per day in area of target ulcer (photographic assessment)<br>Number of subjects with a decrease in area of target ulcer of 50% or more at Visit V16 (EOT) compared to baseline (photographic assessment)<br>Number of subjects with a decrease in area of target ulcer of 100% at Visit V16 (EOT) compared to baseline (remission) (photographic assessment)<br>Degree of erythema and border elevation of the target ulcer compared to baseline at Visits V4, V6, V10, and V16 (EOT) (investigator assessment)<br>Mean change from baseline in pain assessed by Numeric Rating Scale (NRS) at Visits V4, V6, V10, and V16 (EOT)<br>Mean change from baseline in Dermatology Life Quality Index (DLQI) at Visits V4, V6, V10, and V16 (EOT);Timepoint(s) of evaluation of this end point: Interim analysis and End of trial",IFX-1-P2.7,"InflaRx GmbH",,Approved,14/10/2020,,,,,,,,,,,,"No results available","No results available","No results available",,,Yes,False,"          "
NCT04274166,"7 June 2021","Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum","The Efficacy and Safety of Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum",,"Wake Forest University Health Sciences",12/02/2020,"  20200212","10/03/2025 17:03:09",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT04274166,"Not recruiting",No,"18 Years","75 Years",All,01/05/2021,0,Interventional,"Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2","United States"," ","William W Huang, MD. MPH",,,,"Wake Forest University Health Sciences","<br>    Inclusion Criteria:<br><br>    1. Must give written informed consent. 2. Has a diagnosis of pyoderma gangrenosum, as<br>    determined by the investigator based on the following diagnostic criteria4:<br><br>    a. Diagnosis requires both major criteria and at least two minor criteria i. Major criteria<br><br>     1. Rapid progression of a painful, necrolytic cutaneous ulcer with an irregular,<br>       violaceous, and undermined border<br><br>     2. Other causes of cutaneous ulceration have been excluded ii. Minor criteria<br><br>    1. History suggestive of pathergy or clinical finding of cribriform scarring 2. Systemic<br>    diseases associated with PG 3. Histopathologic findings (sterile dermal neutrophilia, ±<br>    mixed inflammation, ± lymphocytic vasculitis) 4. Treatment response (rapid response to<br>    systemic steroid treatment)<br><br>    3. PG global assessment of moderate to severe, with at least one ulcer measuring at least 3<br>    cm in diameter.<br><br>    4. 18 years of age or greater. 5. Must require systemic therapy for their pyoderma<br>    gangrenosum, as determined by the investigator prior to Baseline. Currently prescribed<br>    low-dose corticosteroids (= 10 mg/day), and other medications within one week prior to<br>    investigational drug administration, may be continued with no change in dose or frequency<br>    during the study.<br><br>    Exclusion Criteria:<br><br>     1. Female subjects who are not postmenopausal for at least 1 year, surgically sterile, or<br>       willing to practice effective contraception during the study. Nursing mothers,<br>       pregnant women and women planning to become pregnant while on study are to be<br>       excluded.<br><br>     2. Current enrollment in any investigational study in which the subject is receiving any<br>       type of drug, biologic, or non-drug therapy (participation in registry-type studies is<br>       allowed).<br><br>     3. Serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g.,<br>       pneumonia, septicemia) within the 3 months prior to the first dose of investigational<br>       drug.<br><br>     4. Treatment with another investigational drug or approved therapy for investigational<br>       use within 28 days prior to investigational drug administration.<br><br>     5. Treatment with high dose (>10 mg/day) systemic steroids (prednisone) within one week<br>       prior to investigational drug administration. Treatment with cyclosporine,<br>       thalidomide, methotrexate, mycophenolate mofetil, azathioprine, or other systemic<br>       immunosuppressant agents within the 14 days prior to investigational drug<br>       administration (requirement of a 2-week washout).<br><br>     6. Known HIV+, known viral hepatitis infection, known tuberculosis infection.<br><br>     7. Any subject with a current or history of a malignancy in the last five years<br>       (excluding treated basal cell carcinoma).<br><br>     8. Clinically significant abnormal laboratory measures at screening.<br><br>     9. Known Irritable Bowel Disease-associated PG<br>   ",,"Pyoderma Gangrenosum","Drug: secukinumab 150 mg (2 injections per dose","Efficacy - Investigator Global Assessment (IGA);Efficacy - Investigator Global Assessment (IGA);Efficacy - Investigator Global Assessment (IGA);Efficacy - Investigator Global Assessment (IGA);Efficacy - Investigator Global Assessment (IGA);Efficacy - Investigator Global Assessment (IGA);Efficacy - Investigator Global Assessment (IGA);Efficacy - Investigator Global Assessment (IGA);Efficacy - Investigator Global Assessment (IGA);Efficacy - Subject Global Assessment (SGA);Efficacy - Subject Global Assessment (SGA);Efficacy - Subject Global Assessment (SGA);Efficacy - Subject Global Assessment (SGA);Efficacy - Subject Global Assessment (SGA);Efficacy - Subject Global Assessment (SGA);Efficacy - Subject Global Assessment (SGA);Efficacy - Subject Global Assessment (SGA);Efficacy - Ulcer Lesion Assessment PG Target Lesion;Efficacy - Ulcer Lesion Assessment PG Target Lesion",,Huang_IIT_CAIN457AUS24T;IRB00063109,"Please refer to primary and secondary sponsors",Novartis,,,,,,,,,,,,,,,,,,,Yes,False,"          "
DRKS00017390,"7 April 2025","Breakdown, Identification and Observation of the microenvironment of acute and chronic wounds","Breakdown, Identification and Observation of the microenvironment of acute and chronic wounds - Wound-BIOME                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ",,"Institut für Translationale Wundforschung, Zentrum für biomedizinische Ausbildung und Forschung (ZBAF), Universität Witten/Herdecke",10/07/2019,"  20190710","10/03/2025 17:03:09","German Clinical Trials Register",http://drks.de/search/en/trial/DRKS00017390,Recruiting,No,"18 Years",None,All,18/04/2018,160,observational,"Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: basic science  ",,Germany,Julian-Dario,Rembe,"Stockumer Str. 10",julian-dario.rembe@uni-wh.de,+491626368722,"Institut für Translationale Wundforschung, Zentrum für biomedizinische Ausbildung und Forschung (ZBAF), Universität Witten/Herdecke","Inclusion criteria: 1. Men and women, aged 18 years or older<br>2. Signed informed consent<br>3. Existing wound for longer than 8 weeks ('chronic')<br>OR<br>4. Existing wound for over 24 hours and less than 6 days after traumatic event or surgical intervention ('acute')","Exclusion criteria: 1. Dry necrosis, dry wound bed, no wound bed sampling possible<br>2. Aged < 18 years<br>3. Pregnancy or nursing period<br>4. Wound of malignant entity (e.g. exulcerating tumor)<br>5. Non written consent","acute woundschronic wounds","Group 1: Acute, non-infected wounds (control group; observative, non-interventionell)<br><br>As part of the regular medical wound treatment, sterile wound swabs are obtained from the wound bed of open acute and chronic wounds for biomaterial acquisition. <br>Subsequently, this material is analyzed regarding protein signature, gene expression patterns and microbial occurrence and correlated with the wounds healing stage as well as between acute and chronic wounds. <br>Group 2: diabetic ulceration<br><br>Group 3: arterial ulceration<br>Group 4: venous ulceration<br>Group 5: decubital ulceration<br>Group 6: pyoderma gangrenosum<br>Group 7: other chronic wounds","Goal criterion: Acquisition of biological material for biomolecular analysis of chronic wound entities compared to acute wounds for correlation with healing phase and progression.<br><br>Sampling endpoint is marked by complete wound closure/epithelization making further wound bed swabbing impossible. ",,U1111-1233-9304,"Institut für Translationale Wundforschung, Zentrum für biomedizinische Ausbildung und Forschung (ZBAF), Universität Witten/Herdecke",,Approved,22/03/2018,"Ethik-Kommission der Universität Witten/Herdecke","Alfred-Herrhausen-Str. 50 58448 Witten Germany",+49-2302-926740,sekretariat-ethik@uni-wh.de,,,http://drks.de/search/en/trial/DRKS00017390#studyResults,http://drks.de/search/en/trial/DRKS00017390#studyProtocols,,,,http://drks.de/search/en/trial/DRKS00017390#basicReporting,http://drks.de/search/en/trial/DRKS00017390#basicReporting,http://drks.de/search/en/trial/DRKS00017390#basicReporting,No,,No,False,"          "
NCT03971643,"18 September 2023","Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum","Open Label Exploratory Phase IIa Trial to Investigate the Safety and Efficacy of IFX-1 in Treating Patients With Pyoderma Gangrenosum (OPTIMA)",,"InflaRx GmbH",28/05/2019,"  20190528","10/03/2025 17:03:09",ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT03971643,"Not recruiting",No,"18 Years",N/A,All,16/05/2019,19,Interventional,"Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2","United States;Canada;Poland;Canada;Poland;United States"," ","Prof. Niels C. Riedemann, M.D., Ph.D.",,,,"InflaRx GmbH","<br>    Inclusion Criteria:<br><br>     - Diagnosis of an ulcerative form of pyoderma gangrenosum confirmed by the investigator<br><br>    In addition, the subject must fulfill at least 3 of the following 6 criteria at screening:<br><br>    History of<br><br>     - Pathergy (ulcer occurring at the sites of trauma)<br><br>     - Personal history of inflammatory bowel disease or inflammatory arthritis<br><br>     - History of papule, pustule or vesicle that rapidly ulcerated<br><br>    Clinical examination (or photographic evidence) of<br><br>     - Peripheral erythema, undermining border, and tenderness at site of ulceration<br><br>     - Multiple ulcerations (at least 1 occurring on the lower leg)<br><br>     - Cribriform or """"wrinkled paper"""" scar(s) at sites of healed ulcers<br><br>    Subject has a minimum of 1 evaluable ulcer (=2 cm2) on the lower extremity at screening<br><br>    Exclusion Criteria:<br><br>     - Pyoderma gangrenosum target ulcer for more than 3 years before screening<br><br>     - Surgical wound debridement within the previous 2 weeks before screening<br><br>     - Use of intravenous antibacterials, antivirals, anti-fungals, or anti-parasitic agents<br>       within 30 days before screening<br><br>     - Any drug treatment for pyoderma gangrenosum including corticosteroids (>10 mg),<br>       intralesional steroids, cyclosporine A, biologicals and immunosuppressives (with the<br>       exception of antibiotics for wound superinfection) used within a time of 5 half-lives<br>       of the drug before screening<br>   ",,"Pyoderma Gangrenosum","Drug: vilobelimab","Treatment-emergent Adverse Events (TEAEs), Related TEAEs, Serious TEAEs, and Adverse Events of Special Interest (AESIs)","Number of Patients With Physician's Global Assessment (PGA) Score =3 (Investigator Assessment);Time to Complete Closure of Pyoderma Gangrenosum Target Ulcer (Investigator Assessment) [Days];Percentage Change in Wound Healing (Wound Area) by Photographic Assessment;Percentage Change in Wound Healing (Wound Volume) by Photographic Assessment;Rate of Change Per Day in Area of Target Ulcer by Photographic Assessment From V1 to V16;Number of Patients With = 50% Decrease in Area of Target Ulcer by Photographic Assessment at V16;Number of Patients With 100% Decrease in Area of Target Ulcer at V16;Degree of Erythema of the Target Ulcer at V4, V6, V10 and V16;Border Elevation of the Target Ulcer at Visits V4, V6, V10 and V16;Percentage Change in Pain by Numeric Rating Scale (NRS) at Visits V4, V6, V10 and V16;Percentage Change in Life Quality by DLQI at Visits V4, V6, V10, and V16",IFX-1-P2.7,"Please refer to primary and secondary sponsors","Innovaderm Research Inc.",,,,,,,Yes,14/09/2023,https://clinicaltrials.gov/ct2/show/results/NCT03971643,,,,,,,,,,No,False,"          "
JPRN-jRCTs072180053,"18 July 2025","Study on Therapeutic effects of granulocyte adsorption column (Adacolumn) for pyoderma gangrenosum","Study on Therapeutic effects of granulocyte adsorption column (Adacolumn) for pyoderma gangrenosum - Therapeutic effects of granulocyte adsorption column                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ",,"Higashi Yuko",15/03/2019,"  20190315","10/03/2025 17:03:09",JPRN,https://jrct.mhlw.go.jp/latest-detail/jRCTs072180053,"Not Recruiting",No,">= 20age old","Not applicable",Both,09/11/2015,65,Interventional,"single arm study, open(masking not used), no treatment control/standard of care control, single assignment, treatment purpose",2,,Yuko,Higashi,"8-35-1 Sakuragaoka, Kagoshima City, Kagoshima",higashiy@m.kufm.kagoshima-u.ac.jp,+81-99-275-5388,"Kagoshima University Hospital","Inclusion criteria: Pyoderma gangrenosum","Exclusion criteria: Severe infection","Pyoderma gangrenosum <br>Pyoderma gangrenosum;Pyoderma gangrenosum","Therapy of granulocyte adsorption column","Reduction rate of skin ulcer area","Visual Analogue Scale, physician's global assessment",,,,Approval,13/03/2019,crmc@m2.kufm.kagoshima-u.ac.jp,crmc@m2.kufm.kagoshima-u.ac.jp,+81-99-275-6624,crmc@m2.kufm.kagoshima-u.ac.jp,Yes,31/03/2024,https://pubmed.ncbi.nlm.nih.gov/34369050/,https://jrct.mhlw.go.jp/latest-detail/jRCTs072180053,04/11/2023,09/08/2021,"Granulocyte and monocyte adsorption apheresis was performed for refractory skin ulcers in pyoderma gangrenosum. The achievement rate of skin ulcer area reduction was 68.4%. No serious adverseevents occurred.","Of the 35 cases performed, 15 were males and 20 were females, ranging in age from 21 to 81 years. All cases were treated with granulocyte and monocyte adsorption apheresis because of the single-open trial.","No serious adverse events occurred.","The primary endpoint of skin ulcer area reduction was 68.4%. Secondary endpoints were 3.1 +- 0.2 PGA before treatment and 2.1+- 0.2 after treatment. Pain VAS improved in all cases measured, regardless of effect. CRP was significantly reduced in the effective cases. Other counts such as white blood cell count, neutrophil count, monocyte count, and platelet count did not differ between pre- and post-treatment.",No,"Not applicable",No,False,"          "
NCT03636737,"12 December 2020","Study on the Clinical Features, Comorbidities and Pathologies Associated With Pyoderma Gangrenosum","Retrospective Multicenter Observational Study on the Clinical Features, Comorbidities and Pathologies Associated With Pyoderma Gangrenosum in Patients Diagnosed With This Pathology Between 2000 and 2015",PYODERMA,"Assistance Publique Hopitaux De Marseille",16/08/2018,"  20180816","10/03/2025 17:03:09",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03636737,"Not recruiting",No,N/A,N/A,All,01/12/2018,140,Observational,,,France," ; ; ","EMILIE GARRIDO PRADALIE;PHILIPPE BERBIS, MD;PHILIPPE BERBIS, MD",,;Philippe.BERBIS@ap-hm.fr;Philippe.BERBIS@ap-hm.fr,";0491964962;+33 491964962",APHM;,"<br>    Inclusion Criteria:<br><br>     - 2 major criteria (typical clinical appearance with well-defined ulceration and<br>       purulent or pustule hutches, exclusion of differential diagnoses)<br><br>     - at least 2 minor criteria (among compatible histological aspect, classically<br>       compatible associated pathologies, corticosensitivity of the lesions, pathergie<br>       phenomenon, painful lesions).<br><br>    Exclusion Criteria:<br><br>     - patients with less than 2 major criteria<br><br>     - patients with less than 2 minor criteria<br>   ",,"Pyoderma Gangrenosum","Other: pathology associated","Number of patients",,RCAPHM17_0083,"Please refer to primary and secondary sponsors",,,,,,,,,,,,,,,,,,,,Yes,False,"          "
NCT03311464,"16 March 2021","A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan","A Phase 3 Multicenter, Open-Label, Single Arm Study of the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Subjects in Japan",,AbbVie,12/10/2017,"  20171012","10/03/2025 17:03:09",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03311464,"Not recruiting",No,"18 Years",N/A,All,27/10/2017,22,Interventional,"Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 3",Japan," ","AbbVie Inc.",,,,AbbVie,"<br>    Inclusion Criteria:<br><br>     - Participant must be able and willing to provide written informed consent. If the<br>       participant is < 20 years old, a parent or legal guardian must be willing to give<br>       written informed consent<br><br>     - Participants must have a diagnosis of ulcerative (classic) PG made by the Investigator<br><br>     - Participants must have demonstrated an inadequate response to conventional PG therapy<br>       or in the opinion of the Investigator they are not a suitable candidate for<br>       conventional PG treatment.<br><br>    Exclusion Criteria:<br><br>     - Participants with pustular, bullous/atypical, or vegetative variants of PG<br><br>     - Participants with clinical evidence of ulceration that is non-PG related, vasculitis,<br>       thrombosisprone conditions, or monoclonal gammopathy<br><br>     - Participants with a histopathological finding that is consistent with a diagnosis<br>       other than PG<br><br>     - Participants receiving a therapeutic dose of prednisolone<br><br>     - Participants with prior exposure to adalimumab or previous participation in an<br>       adalimumab clinical study.<br>   ",,"Pyoderma Gangrenosum","Drug: adalimumab","Proportion of participants who have achieved target Pyoderma Gangrenosum Area Reduction (PGAR)","Proportion of participants achieving Physician's Global Assessment (PGA) 0 or 1;Mean time to occurrence of new PG ulcers;Change from Baseline in total number of active ulcers;Change from Baseline in Dermatology Life Quality Index (DLQI);Changes from Baseline in total ulcer area;Proportion of participants with inflammation reduction as assessed on an Investigator Inflammation Assessment (IIA) Score;Mean time to occurrence of a new PG ulcer(s);Mean time to healing of target ulcer;Proportion of participants achieving healing per PGAR for the target ulcer;Proportion of participants who have achieved target PGAR;Percentage change in target Pyoderma Gangrenosum (PG) ulcer area;Proportion of participants achieving PGA 0;Change from Baseline in Pain as measured by Numerical Rating Scale (NRS);Changes from baseline in the proportion of participants taking analgesics;Velocities of healing;Proportion of participants achieving ulcer healing as assessed by PGAR;Proportion of participants achieving PGA 0 of all PG ulcers;Mean time to relapse of the target PG ulcer;Mean time to healing as defined by PGAR",M16-119,"Please refer to primary and secondary sponsors",,,,,,,,,,,,,,,,,,,,Yes,False,"          "
NCT03137160,"4 March 2024","An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum","An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum",,"Ohio State University",27/04/2017,"  20170427","10/03/2025 17:03:09",ClinicalTrials.gov,https://clinicaltrials.gov/ct2/show/NCT03137160,"Not recruiting",No,"18 Years",N/A,All,04/05/2017,4,Interventional,"Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2","United States"," ","Benjamin Kaffenberger, MD",,,,Dermatologist,"<br>    Inclusion Criteria:<br><br>     - Major inclusion criteria:<br><br>     - Have a clinical diagnosis of classic Pyoderma Gangrenosum for at least 3 months as<br>       determined by the investigator and an external reviewer on the basis of results from<br>       clinical, histological and laboratory assessments<br><br>     - At screening, have a Pyoderma Gangrenosum ulcer characterized by 'item a' AND 3/5<br>       features in 'item b' OR 2/5 features in 'item b' with support from one of the<br>       conditions listed in c.<br><br>       a. Stable or increasing size within 2 months preceding screening by patient report or<br>       documentation b. Features such as violaceous border, undermining, d. Intralesional<br>       corticosteroids within 8 weeks of day 0; topical immunomodulators are permitted.<br><br>       e. Wound debridement within 2 weeks of Day 0; dressing changes allowed per<br>       investigator discretion.<br><br>       g. Systemic antibiotics within 2 weeks of Day 0 h. Live, attenuated vaccines within 3<br>       months of Day 0; or live, seasonal-flu- or H1N1 vaccines within 2 weeks of Day 0.<br>       Note: recombinant- and/or killed vaccines are permitted.<br><br>       i. Hyperbaric treatment within 4 weeks of Day 0 j. Investigational drug or<br>       investigational device within 30 days or 5 half-lives of Day 0, whichever is longer k.<br>       Prior exposure to ixekizumab l. Other treatments not described above should be<br>       maintained at a stable dose and frequency throughout the study as best as possible 13.<br>       Major, general surgery within 3 months of screening, or anticipated general surgery<br>       during the study period 14. Pregnancy, plans to become pregnant during the course of<br>       the study, delivery within 3 months of screening, or breast-feeding 15. If previous<br>       use of cyclosporine or systemic corticosteroids, failure to have any<br>       stabilization/response is exclusionary. This potentially indicates the disease is not<br>       Pyoderma Gangrenosum.<br><br>    Exclusion Criteria:<br><br>     - Major exclusion criteria:<br><br>        1. Any condition (e.g., psychiatric illness, severe alcoholism, or drug abuse) or<br>         situation that may compromise the ability of the subject to give written informed<br>         consent, may put the subject at significant risk, may jeopardize the subject's<br>         safety after exposure to the study drug, may confound the study results, or may<br>         interfere significantly with the subject's participation in the study<br><br>        2. History of malignancy within 2 years of screening other than carcinoma in situ of<br>         the cervix or adequately treated, non-metastatic, squamous or basal cell<br>         carcinoma of the skin<br><br>        3. History of seropositivity for HIV antibody; active or carrier status of hepatitis<br>         B [surface antigen (HBsAg) positive, or core antibody (anti-HBc) positive with<br>         negative surface antibody]; active hepatitis C (i.e. not treated or not cleared<br>         spontaneously, as confirmed by HCV PCR)<br><br>        4. History of severe allergic or anaphylactic reaction to monoclonal antibodies<br><br>        5. Systemic infection (excluding wound colonization) requiring oral antibiotics<br>         within 2 weeks of Day 0<br><br>        6. History of the following treatments:<br><br>          1. Anti-Tumor Necrosis Factor or other biologic therapies within 5 half-lives<br>            of screening<br><br>          2. Changes (addition, discontinuation, or changes in dose) in immunosuppressive<br>            medication (including cyclosporine, azathioprine, methotrexate,<br>            mycophenolate mofetil, apremilast, dapsone, or corticosteroids) within 2<br>            months of Day 0<br><br>          3. Systemic corticosteroids > 20 mg per day (prednisone or prednisone<br>            equivalent) within 8 weeks of Day 0, or change in dose within 8 weeks of Day<br>            0. Steroids may be tapered (although not increased above the Day 0 dose)<br>            during the trial as determined by the investigator.<br><br>    they are prescribed at stable doses for two months prior to baseline and are 20 mg or less<br>    per day of prednisone or other equivalently-dosed corticosteroids.<br><br>    4. Intralesional corticosteroids within 4 weeks of screening and during the study are not<br>    permitted 5. Other therapies that are non-immunosuppressive and non-investigational can be<br>    started or continued at physician discretion provided the medicine has no history of<br>    association with progressive multifocal leukoencephalopathy. Antibiotics may be used as<br>    needed for evidence of superinfection, positive culture results, malodor, green discharge,<br>    etc.<br>   ",,"Pyoderma Gangrenosum","Biological: Ixekizumab","The Proportion of Subjects Achieving 2-point Reduction in the 5-point Investigator Global Assessment (IGA) for the Target Ulcer at Week 12",,2017H0045,"Please refer to primary and secondary sponsors","Eli Lilly and Company",,,,,,,Yes,06/06/2022,https://clinicaltrials.gov/ct2/show/results/NCT03137160,,,,,,,,,,Yes,False,"          "
NCT03072953,"12 December 2020","Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum","A Phase 2a, Open-label, Proof of Concept Study to Determine the Efficacy and Safety of Etrasimod (APD334) in Patients With Pyoderma Gangrenosum",,"Arena Pharmaceuticals",17/02/2017,"  20170217","10/03/2025 17:03:09",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT03072953,"Not recruiting",No,"18 Years","80 Years",All,07/06/2017,2,Interventional,"Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2","Australia;New Zealand;Australia;New Zealand"," ","Arena CT.gov Administrator",,,,"Arena Pharmaceuticals","<br>    Inclusion Criteria:<br><br>     1. Male or female (18-80 years).<br><br>     2. Able to provide a signed informed consent prior to any study related procedure being<br>       conducted.<br><br>     3. Diagnosis of PG with active, non-healing ulcer.<br><br>     4. Considered to be in stable health in the opinion of the investigator as determined by:<br><br>        1. A screening physical examination with no clinically significant abnormalities<br>         unrelated to PG.<br><br>        2. Vital signs at screening: pulse rate = 55 bpm, systolic blood pressure = 90 mmHg,<br>         and diastolic blood pressure = 55 mmHg.<br><br>        3. Liver function tests (alanine aminotransferase/aspartate aminotransferase,<br>         bilirubin and alkaline phosphatase) < 2x the upper limit of normal.<br><br>        4. All other pre-study clinical laboratory findings within normal range, or if<br>         outside of the normal range are not deemed clinically significant in the opinion<br>         of the investigator with exemption to leucopenia and lymphopenia - please refer<br>         to exclusion criterion 24.<br><br>        5. No clinical abnormalities noted in the12-lead electrocardiogram in the opinion of<br>         the investigator (Refer also to exclusion criterion 13).<br><br>        6. No evidence of macular edema in an ophthalmology evaluation (performed by an<br>         ophthalmologist), supported with optical coherence tomography, where available<br>         (dependent on site capability) at screening.<br><br>     5. Eligible male and female participants must agree not to participate in a conception<br>       process (i.e. active attempt to let female partner to become pregnant or to<br>       impregnate, sperm donation, oocyte donation, in vitro fertilization) for at least 30<br>       days after the last dose of study drug.<br><br>    Non-sterile participants who are sexually active must take adequate contraception measures.<br><br>    Exclusion Criteria:<br><br>     1. Clinically significant infection as judged by the investigator with an end date less<br>       than 6-weeks prior to treatment start (Day 1). In case of infection requiring<br>       hospitalization or intravenous antimicrobial therapy, or opportunistic infection, this<br>       infection must have ended at least 8 weeks prior to Day 1.<br><br>     2. Infection with hepatitis C virus anytime in the past; confirmed active infection with<br>       hepatitis B virus at screening.<br><br>     3. History of severe renal or severe hepatic impairment.<br><br>     4. Current active or latent tuberculosis (TB).<br><br>     5. A positive diagnostic TB test at screening.<br><br>     6. Exposure to B-cell or T-cell targeted therapies (such as natalizumab, rituximab,<br>       abatacept) within 5 half-lives prior to Day 1.<br><br>     7. Exposure to other immunosuppressive, immunomodulating or antineoplastic agents.<br><br>     8. Receipt of any investigational agent within 30 days or 5 half lives (whichever is<br>       longer), prior to Day 1.<br><br>     9. Use of moderate to strong inhibitors of CYP2C9.<br><br>     10. Abnormal forced expiratory volume (FEV1) or forced vital capacity (FVC).<br><br>     11. Any known history of congenital or acquired immuno-deficiency.<br><br>     12. Recent history (within 6 months of screening visit) of cardio- or cerebrovascular<br>       disease, acute coronary syndrome, myocardial infarction, unstable angina,<br>       cerebro-vascular accident, including transient ischemic attack.<br><br>     13. History or presence of cardiac arrhythmia, conduction system disease, or use of Class<br>       Ia or Class III anti arrhythmic agents, or baseline QTc = 500 msec.<br><br>     14. Congestive heart failure (NYHA III or NYHA IV)<br><br>     15. Any surgical procedure requiring general anesthesia within 30 days prior to Day 1 or<br>       plans to undergo major surgery during the study period.<br><br>     16. History of retinal macular edema.<br><br>     17. History of or signs and symptoms of progressive multifocal leukoencephalopathy (PML)<br>       as assessed by the PML checklist at screening.<br><br>     18. History of more than one episode of herpes zoster or any episode of disseminated<br>       zoster.<br><br>     19. Participants without documented positive varicella zoster virus (VZV) IgG antibody<br>       status or participants who have not completed VZV vaccination within 6 weeks prior to<br>       Day 1.<br><br>     20. Receipt of live vaccine within 6 weeks prior to Day 1.<br><br>     21. History of lymphoproliferative disorder, lymphoma, leukemia, myeloproliferative<br>       disorder, or multiple myeloma.<br><br>     22. History of malignancy except for adequately treated basal cell skin cancer and in situ<br>       carcinoma of the cervix of the uterus that have been completely excised with<br>       documented, clear margins.<br><br>     23. History of severe allergic or anaphylactic reactions requiring medical attention.<br><br>     24. Leukopenia or lymphopenia at screening.<br><br>     25. Current or recent history (within 1 year prior to Day 1) of alcohol dependence or<br>       illicit drug use.<br><br>     26. Active psychiatric problems that, in the investigator's opinion, may interfere with<br>       compliance with the study procedures.<br><br>     27. History of any other clinically significant medical condition that, in the<br>       investigator's opinion, would preclude participant from safe participation in the<br>       study.<br><br>     28. Inability to attend all the study visits or comply with study procedures.<br><br>     29. Prior exposure to etrasimod (APD334) or prior participation in any study of etrasimod<br>       (APD334).<br>   ",,"Pyoderma Gangrenosum","Drug: APD334","Exploratory endpoint - Change from baseline in: Physician Global Assessments for active skin manifestations.;Exploratory endpoint - Change from baseline in Patient Global Assessments for active skin manifestations: visual analog scale for assessment of severity of the disease and severity of pain by patient.;Exploratory endpoint - Change from baseline in Dermatology Life Quality Index (to measure how much a patient's life is affected through their skin problems).;Exploratory endpoint - Change from baseline in C-reactive protein levels.;Exploratory endpoint - Assessments of target lesions.;Exploratory endpoint - Assessment of punch biopsies.",,APD334-011,"Please refer to primary and secondary sponsors",,,,,,,,,,,,,,,,,,,,Yes,False,"          "
NCT02733094,"24 April 2023","Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum","Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum",,"Technical University of Munich",28/03/2016,"  20160328","10/03/2025 17:03:09",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02733094,"Not recruiting",No,"18 Years","75 Years",All,01/04/2016,8,Interventional,"Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 1/Phase 2",Germany," ","Kilian Eyerich, MD, PhD",,,,"Technical University of Munich","<br>    - Key Inclusion Criteria:<br><br>        - Confirmed diagnosis of Pyoderma gangrenosum<br><br>        - Biopsy-proven, non-healing ulcer with primarily neutrophil infiltration,<br>         regardless of size and location<br><br>        - Characterization of target lesion (size, PGA, duration)<br><br>        - 18-75 years of age<br><br>        - Body weight = 40 kg and = 160 kg<br><br>        - Signed informed consent<br><br>     - Key Exclusion Criteria:<br><br>        - Permanent severe diseases, especially those affecting the immune system<br><br>        - Pregnancy or breast feeding<br><br>        - History or presence of epilepsy, significant neurological disorders,<br>         cerebrovascular attacks or ischemia<br><br>        - Myocardial infarction or cardiac arrhythmia which requires drug therapy<br><br>        - Evidence of severe renal dysfunction or significant hepatic disease<br><br>        - History of irritable bowel disease<br><br>        - History of lymphoproliferative disorders<br><br>        - Evidence for active infection including but not limited to active tuberculosis,<br>         HIV or hepatitis B/C that in the opinion of the investigator would compromise the<br>         patient's ability to tolerate therapy<br><br>        - History of malignancy of any organ system, treated or untreated, whether or not<br>         there is evidence of local recurrence or metastases, with the exception of<br>         localized basal cell carcinoma of the skin<br>   ",,"Pyoderma Gangrenosum","Drug: Secukinumab","Change of the Physician's global assessment","Change in surface area of lesions of pyoderma gangrenosum (two-dimensional surface in mm²);Assessment of patient's quality of life;Measurement of serum C reactive protein (mg/dl);Measurement of leukocyte counts (x10.e3/µl);Measurement of blood sedimentation rate (mm/h);Immunohistochemical analysis of IL-17+ immune cells",CAIN547ADE01T,"Please refer to primary and secondary sponsors",Novartis,,,,,,,,,,,,,,,,,,,Yes,False,"          "
EUCTR2015-000762-65-DE,"18 March 2020","Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosu","Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosum                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ",,"Technische Universität München, School of Medicine, represented by Dean",25/06/2015,"  20150625","10/03/2025 17:03:09","EU Clinical Trials Register",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-000762-65,"Not Recruiting",No,,,"<br>Female: yes<br>Male: yes<br>",09/07/2015,7,"Interventional clinical trial of medicinal product","Controlled: no
Randomised: no
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: no
Number of treatment arms in the trial: 1
","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
",Germany,"Studienzentrum Dermatologie",,"Biedersteinerstr. 29",kilian.eyerich@tum.de,"+49894140 3579","Department of Dermatology and Allergy Technische Universität München ","Inclusion criteria: <br>Confirmed diagnosis of pyoderma gangrenosum, biopsy-proven, non-healing ulcer with primarily neutrophil infiltration, regardless of size and location, characterization of target lesion (size, PGA, duration, age 18-75 years of age, body weight = 40 kg and = 160 kg, signed informed consent from patient, the first two patients of the trial must have received one other treatment for pyoderma gangrenosum before being included. <br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 7<br>F.1.3 Elderly (>=65 years) no<br>F.1.3.1 Number of subjects for this age range <br>","Exclusion criteria: <br>Permanent severe diseases, especially those affecting the immune system, pregnancy or breast feeding, history or presence of epilepsy, significant neurological disorders, cerebrovascular attacks or ischemia, myocardial infarction or cardiac arrhythmia which requires drug therapy, evidence of severe renal dysfunction or significant hepatic disease, history of irritable bowel disease, history of lymphoproliferative disorders, simultaneous participation in another clinical trial or participation in another clinical trial during the last 6 months. <br>","Pyoderma gangrenosum is an autoinflammatory disease, characterized by relapsing, painful ulcers of the skin. Treatment of PG is difficult. Patients suffer from long hospitalization, pain and reduced life quality. New therapeutic strategies are needed. Immunohistological staining show a high amount of IL-17 in PG. IL-17+ immune cells were located in proximity to cellular damage, indicating an involvement in the pathogenesis. Targeting IL-17 with neutralizing IL-17 antibodies seems promising. <br>MedDRA version: 20.0Level: PTClassification code 10037635Term: Pyoderma gangrenosumSystem Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]","<br>Trade Name: Cosentyx®<br>Product Name: Cosentyx<br>Product Code: EU/1/14/980/002; EU/1/14/980/003<br>Pharmaceutical Form: Solution and suspension for suspension for injection in pre-filled syringe<br><br>","Main Objective: To evaluate efficacy and tolerability of secukinumab in patients with pyoderma gangrenosum after 16 week treatment with 300 mg s.c. secukinumab.;Secondary Objective: Not applicable;Primary end point(s): Change of the Physician's global assessment (Grade 0-4) of the target lesion;Timepoint(s) of evaluation of this end point: Week 16","Secondary end point(s): a) Change in surface area of lesions of pyoderma gangrenosum <br>b) Laboratory measurements <br>c) Patient's quality of life (measured by """"dermatology life quality index, DLQI"""")<br>d) Immunohistochemical analysis of IL-17+ immune cells <br>e) Change of the Physician's global assessment (Grade 0-4) of the target lesion<br>;Timepoint(s) of evaluation of this end point: a) Week 2, 4, 8, 16, 28, 32, 40<br>b) Week 2, 4, 8, 16, 28, 32, 40<br>c) Week 2, 4, 8, 16, 28, 32, 40 <br>d) Week 16 as compared to week 0<br>e) Week 32",CAIN457ADE01T,"Novartis Pharmaceuticals AG",,Approved,01/07/2015,,,,,,,,,,,,"No results available","No results available","No results available",,,Yes,False,"          "
NCT02366260,"2 March 2015","An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum","A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum",,"MedDerm Associates",11/02/2015,"  20150211","10/03/2025 17:03:09",ClinicalTrials.gov,http://clinicaltrials.gov/show/NCT02366260,Recruiting,No,"18 Years",N/A,Both,01/02/2015,5,Interventional,"Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment","Phase 3","United States"," ; ; ","Michelle Pelle, M.D.;XOMA;Karla Anselmo, CRC",,;;clinicaltrials@medderm.net,;;619-243-7015,"MedDerm Associates;","<br>    Inclusion Criteria:<br><br>     - A clinical diagnosis of classic pyoderma gangrenosum<br><br>     - An active pyoderma gangrenosum ulcer<br><br>     - A willingness to use contraceptive methods to prevent pregnancy during the study<br><br>    Exclusion Criteria:<br><br>     - A clinical evidence of acute infected pyoderma gangrenosum<br><br>     - Active Hepatitis B, C, and postive Quantiferon TB test result<br><br>     - History of HIV<br><br>     - History of malignancy, clinically significant recurrent or chronic systemic infection<br><br>     - History of severe allergic or anaphylactic reaction to monoclonal antibodies<br><br>     - Washout periods for certain treatments applies. Protocol-defined inclusion/exclusion<br>       criteria may apply.<br>   ",,"Pyoderma Gangrenosum","Drug: Gevokizumab;Drug: Placebo","The proportion of subjects at Day 126 with complete closure of the PG target ulcer confirmed 2 weeks later and without the need for rescue treatment.","The proportion of subjects at Day 126 with a reduction in target ulcer area of 50% or more had a baseline target ulcer area greater or equal to 25cm and less than 50cm.",X052172,"Please refer to primary and secondary sponsors","XOMA (US) LLC",,,,,,,,,,,,,,,,,,,No,False,"          "
NCT02326740,"9 May 2016","An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum","A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum",,"XOMA (US) LLC",22/12/2014,"  20141222","10/03/2025 17:03:09",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02326740,"Not recruiting",No,"18 Years",N/A,Both,01/12/2014,9,Interventional,"Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment","Phase 3","United States;Australia;Canada;Australia;Canada;United States",,,,,,,"<br>    Inclusion Criteria:<br><br>     - A clinical diagnosis of classic pyoderma gangrenosum<br><br>     - An active pyoderma gangrenosum ulcer<br><br>     - Contraceptive measures adequate to prevent pregnancy during the study<br><br>    Exclusion Criteria:<br><br>     - Clinical evidence of acutely infected pyoderma gangrenosum<br><br>     - History of allergic or anaphylactic reactions to monoclonal antibodies<br><br>     - History of recurrent or chronic systemic infections<br><br>     - Female subjects who are pregnant, planning to become pregnant, have recently<br>       delivered, or are breast-feeding<br><br>    Other protocol-defined inclusion/exclusion criteria may apply<br>   ",,"Pyoderma Gangrenosum","Drug: gevokizumab;Drug: Placebo;Drug: gevokizumab open-label","The proportion of subjects at Day 126 with complete closure of the PG target ulcer confirmed 2 weeks later (at Day 140) and without the need for rescue treatment","The proportions of subjects at Day 126 with a reduction in the target ulcer area of = 75% or = 90% from baseline.",X052173,"Please refer to primary and secondary sponsors",,,,,,,,,,,,,,,,,,,,No,False,"          "
NCT02318914,"9 May 2016","A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum","A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients With Pyoderma Gangrenosum",,"XOMA (US) LLC",08/12/2014,"  20141208","10/03/2025 17:03:09",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02318914,"Not recruiting",No,"18 Years",N/A,Both,01/11/2014,15,Interventional,"Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment","Phase 3","United States;Australia;Canada;Australia;Canada;United States",,,,,,,"<br>    Inclusion Criteria:<br><br>     - Individuals who participated in a previous study of gevokizumab in PG<br><br>     - A clinical diagnosis of classic pyoderma gangrenosum<br><br>     - Contraceptive measures adequate to prevent pregnancy during the study<br><br>    Exclusion Criteria:<br><br>     - Clinical evidence of acutely infected pyoderma gangrenosum<br><br>     - History of allergic or anaphylactic reactions to monoclonal antibodies<br><br>     - History of recurrent or chronic systemic infections<br><br>     - Female subjects who are pregnant, planning to become pregnant, have recently<br>       delivered, or are breast-feeding<br><br>    Other protocol-defined inclusion/exclusion criteria may apply<br>   ",,"Pyoderma Gangrenosum","Drug: gevokizumab","Evaluation of treatment-emergent adverse events;;Changes from baseline vital signs, physical examination results, and laboratory test results;Changes from baseline concomitant medications use",,X052171,"Please refer to primary and secondary sponsors",,,,,,,,,,,,,,,,,,,,No,False,"          "
NCT02315417,"9 May 2016","An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum","A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum",,"XOMA (US) LLC",05/12/2014,"  20141205","10/03/2025 17:03:09",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT02315417,"Not recruiting",No,"18 Years",N/A,Both,01/11/2014,16,Interventional,"Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment","Phase 3","United States",,,,,,,"<br>    Inclusion Criteria:<br><br>     - A clinical diagnosis of classic pyoderma gangrenosum<br><br>     - An active pyoderma gangrenosum ulcer<br><br>     - Contraceptive measures adequate to prevent pregnancy during the study<br><br>    Exclusion Criteria:<br><br>     - Clinical evidence of acutely infected pyoderma gangrenosum<br><br>     - History of allergic or anaphylactic reactions to monoclonal antibodies<br><br>     - History of recurrent or chronic systemic infections<br><br>     - Female subjects who are pregnant, planning to become pregnant, have recently<br>       delivered, or are breast-feeding<br><br>    Other protocol-defined inclusion/exclusion criteria may apply<br>   ",,"Pyoderma Gangrenosum","Drug: gevokizumab;Drug: Placebo;Drug: gevokizumab open-label","The proportion of subjects at Day 126 with complete closure of the PG target ulcer confirmed 2 weeks later (at Day 140) and without the need for rescue treatment","The proportions of subjects at Day 126 with a reduction in the target ulcer area of = 75% or = 90% from baseline.",X052172,"Please refer to primary and secondary sponsors",,,,,,,,,,,,,,,,,,,,No,False,"          "
NCT01965613,"8 September 2025","A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum","A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum",,"Janssen Research & Development, LLC",15/10/2013,"  20131015","10/03/2025 17:03:09",ClinicalTrials.gov,https://clinicaltrials.gov/study/NCT01965613,"Not recruiting",No,"18 Years",N/A,All,31/01/2014,10,Interventional,"Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2","United States"," ","Janssen Research & Development, LLC Clinical Trial",,,,"Janssen Research & Development, LLC","Inclusion Criteria:<br><br> 1. Age: =18<br><br> 2. History of pyoderma gangrenosum with or without other systemic disease.<br><br>Exclusion Criteria:<br><br> 1. Treatment with any biologicals (including intravenous immunoglobulin) or<br>   investigational agents within the last 4 weeks (or 5 half-lives, whichever is<br>   longer).<br><br> 2. Treatment with corticosteroids or cyclosporine within the last 2 weeks.",,"Pyoderma Gangrenosum","Biological: Xilonix","Change in Physician's Wound Assessment & Patient's Global Assessment",,2013-PT025,"Please refer to primary and secondary sponsors",,,,,,,,,,,,,,,,,,,,Yes,False,"          "
NCT01952275,"10 October 2016","Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases","Assessment of the Enrichment of Rare Coding Genetic Variants in Patients Affected by Neutrophil-Mediated Inflammatory Dermatoses",NEUTROGENE,"University of Zurich",17/09/2013,"  20130917","10/03/2025 17:03:09",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01952275,Recruiting,No,N/A,"120 Years",Both,01/01/2014,600,Observational,"Observational Model: Case-Only, Time Perspective: Cross-Sectional",N/A,Switzerland;Switzerland," ; ; ; ","Alexander Navarini, MD;Alexander Navarini, MD;Alexander Navarini, MD;Alexander Navarini, MD",,;alexander.navarini@usz.ch;;alexander.navarini@usz.ch,;;;,"University Hospital Zurich, Dept. of Dermatology;;University Hospital Zurich, Dept. of Dermatology;","<br>    Inclusion criteria:<br><br>     - History of NMID or active disease.<br><br>     - Informed consent.<br><br>    Exclusion criteria:<br><br>    - No consent to either part of the study.<br>   ;<br>    Inclusion criteria:<br><br>     - History of NMID or active disease.<br><br>     - Informed consent.<br><br>    Exclusion criteria:<br><br>    - No consent to either part of the study.<br>   ",,"Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue;Pyoderma Gangrenosum;Erosive Pustular Dermatosis of the Scalp;Sweet's Syndrome;Behcet's Disease;Bowel-associated Dermatosis-arthritis Syndrome;Pustular Psoriasis;Acute Generalized Exanthematous Pustulosis;Keratoderma Blenorrhagicum;Sneddon-Wilkinson Disease;IgA Pemphigus;Amicrobial Pustulosis of the Folds;Infantile Acropustulosis;Transient Neonatal Pustulosis;Neutrophilic Eccrine Hidradenitis;Rheumatoid Neutrophilic Dermatitis;Neutrophilic Urticaria;Still's Disease;Erythema Marginatum;Unclassified Periodic Fever Syndromes / Autoinflammatory Syndromes;Dermatitis Herpetiformis;Linear IgA Bullous Dermatosis;Bullous Systemic Lupus Erythematosus;Inflammatory Epidermolysis Bullosa Aquisita;Neutrophilic Dermatosis of the Dorsal Hands (Pustular Vasculitis);Small Vessel Vasculitis Including Urticarial Vasculitis;Erythema Elevatum Diutinum;Medium Vessel Vasculitis;Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue;Pyoderma Gangrenosum;Erosive Pustular Dermatosis of the Scalp;Sweet's Syndrome;Behcet's Disease;Bowel-associated Dermatosis-arthritis Syndrome;Pustular Psoriasis;Acute Generalized Exanthematous Pustulosis;Keratoderma Blenorrhagicum;Sneddon-Wilkinson Disease;IgA Pemphigus;Amicrobial Pustulosis of the Folds;Infantile Acropustulosis;Transient Neonatal Pustulosis;Neutrophilic Eccrine Hidradenitis;Rheumatoid Neutrophilic Dermatitis;Neutrophilic Urticaria;Still's Disease;Erythema Marginatum;Unclassified Periodic Fever Syndromes / Autoinflammatory Syndromes;Dermatitis Herpetiformis;Linear IgA Bullous Dermatosis;Bullous Systemic Lupus Erythematosus;Inflammatory Epidermolysis Bullosa Aquisita;Neutrophilic Dermatosis of the Dorsal Hands (Pustular Vasculitis);Small Vessel Vasculitis Including Urticarial Vasculitis;Erythema Elevatum Diutinum;Medium Vessel Vasculitis","Procedure: Collection of biological samples;Procedure: Collection of biological samples","Enrichment of rare coding genetic variants;Enrichment of rare coding genetic variants",,USZ-DER-AAN-019;USZ-DER-AAN-019,"Please refer to primary and secondary sponsors;Please refer to primary and secondary sponsors",,,,,,,,,,,,,,,,,,,,Yes,False,"          "
NCT01882504,"15 February 2016","Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum","An Open-label, Proof of Concept Study of Gevokizumab in the Treatment of the Acute, Inflammatory Phase of Pyoderma Gangrenosum",,"XOMA (US) LLC",17/06/2013,"  20130617","10/03/2025 17:03:09",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01882504,"Not recruiting",No,"18 Years",N/A,Both,01/05/2013,8,Interventional,"Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment","Phase 2","United States",,,,,,,"<br>    Inclusion Criteria:<br><br>     - An established diagnosis of pyoderma gangrenosum<br><br>     - Currently experiencing an inflammatory episode of pyoderma gangrenosum<br><br>     - Contraceptive measures adequate to prevent pregnancy during the study<br><br>    Exclusion Criteria:<br><br>     - Clinical evidence of acutely infected pyoderma gangrenosum<br><br>     - History of allergic or anaphylactic reactions to monoclonal antibodies<br><br>     - History of recurrent or chronic systemic infections<br><br>     - Female subjects who are pregnant, planning to become pregnant, have recently<br>       delivered, or are breast-feeding<br><br>    Other protocol-defined inclusion/exclusion criteria may apply<br>   ",,"Pyoderma Gangrenosum","Drug: gevokizumab","Improvement in the Investigator's Assessment of the pyoderma gangrenosum target ulcer",,X052170,"Please refer to primary and secondary sponsors",,,,,,,,,,,,,,,,,,,,No,False,"          "
EUCTR2011-002920-41-DE,"8 August 2022","Stelara® (Ustekinumab) treatment in Patients with Pyoderma gangrenosum","Open-label Trial of Stelara® (Ustekinumab) In Patients with Pyoderma gangrenosum – an open, non-placebo controlled pilot study with 10 patients. - SPG-Trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ",,"University Hospital Tübingen",24/08/2011,"  20110824","10/03/2025 17:03:09","EU Clinical Trials Register",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-002920-41,"Not Recruiting",No,,,"<br>Female: yes<br>Male: yes<br>",04/01/2012,10,"Interventional clinical trial of medicinal product","Controlled: no<br>Randomised: no<br>Open: no<br>Single blind: no<br>Double blind: no<br>Parallel group: no<br>Cross over: no<br>Other: no<br>If controlled, specify comparator, Other Medicinial Product: no<br>Placebo: no<br>Other: no<br>","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
",Germany,"Coordinating Investigator",,"Liebermeisterstr. 25",tilo.biedermann@med.uni-tuebingen.de,"00490707129 80836","University Department of Dermatology","Inclusion criteria: <br>1.Clinical diagnosis of PG, previously systemically untreated (with the exception of systemic corticosteroids)<br><br>2.Measurable disease parameters of PG (color photograph with a ruler).<br><br>3.Patients >= 18 years of age<br><br>4.Female patients of childbearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug.<br><br>5.Written, voluntary informed consent. Consent must include investigational use of parts of the obtained tissue material. <br><br>6.Screening laboratory test results within the following parameters:<br>-Haemoglobin=10g/dL<br>-White blood cells=3.5 x 109/L<br>-Neutrophils=1.5 x 109/L<br>-Platelets=100 x 109/L<br>-Serum creatinine = 1.5 mg/dL (or = 133 mol/L)<br>-Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase levels must not exceed three times the upper limit of the normal range for laboratory conducting the test.<br>7.Eligible according the tuberculosis (TB) criteria<br><br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 10<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 10<br>","Exclusion criteria: <br>1.Female patients who are pregnant or breast-feeding.<br><br>2.Known diagnosis of human immunodeficiency virus (HIV) infection, Hepatitis B or Hepatitis C.<br><br>3.Diagnosed with active or latent TB infection during screening.<br><br>4.Any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.<br><br>5.Currently receiving any other biologic agent.<br><br>6.Have previously failed treatment with any therapeutic agent with the exception of systemic corticosteroids.<br><br>7. Have previously received any treatment agent directly targeted at reducing IL-12 and/or IL-23.<br><br>8.Have received, within 2 weeks prior to the first dose of ustekinumab, a live virus or bacterial vaccination.<br><br>9.Have received, or are expected to receive, a BCG vaccination within 12 months prior to screening, during study, or within 12 months after the last administration of study agent.<br><br>10.Have a serious infection (eg sepsis, pneumonia or pyelonephritis).<br><br>11.Have a transplanted organ (with exception of a corneal transplantat in situ).<br><br>12.Have a known history of lymphoproliferative disease.<br><br>13.Have any known malignancies or have history of malignancy (with the exception of basal cell carcinoma, squamous cell carcinoma with tumor thickness =2mm, or cervical carcinoma in situ that has been treated with no evidence of reccurence within 1 year prior to the first administration of study agent).<br><br>14.Have a known hypersenstitivity to ustekinumab or any of its excipients.<br><br>15.Is a prisoner<br><br>16.Participation in another clinical trial whilst this study or within the last 30 days preliminary to this study<br><br>17.Have any condition that, in the opinion of the investigator, would compromise the well being of the patient or the study.<br><br>","Patients with a clinical diagnosis of Pyoderma gangrenosum <br>MedDRA version: 14.1Level: LLTClassification code 10037634Term: Pyoderma gangenosumSystem Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]","<br>Trade Name: Stelara<br>Product Name: Ustekinumab<br>Pharmaceutical Form: Solution for injection<br>CAS Number: 815610-63-0<br>Other descriptive name: USTEKINUMAB<br>Concentration unit: mg milligram(s)<br>Concentration type: range<br>Concentration number: 45-90<br><br>","Main Objective: To confirm the efficacy and immunological response of Stelara® therapy in patients with PG;Primary end point(s): Change of the PG-inflammation SCORE from baseline to week 28;Timepoint(s) of evaluation of this end point: week 28 ;Secondary Objective: - To assess changes in PG-inflammation Score, Wound Score and Visual Analogue Pain Scale (VAPS).  <br><br>- To assess the safety and tolerability of Stelara in patients with PG. <br><br>- To assess, where feasible, the functional significance of the expression pattern of inflammatory cytokines, particularly IL-23, in PG tissue as obtained by biopsies before the beginning of and after the treatment with Stelara and by blood samples before, during and after treatment with Stelara<br>•Evaluation of the expression of these cytokines and/or associated inflammatory molecules<br>•Assessment of the type of Th immune response before, during and after treatment with Stelara<br>•Correlation of the results from the analyses mentioned above with the clinical outcome of PG patients.<br><br>- To asses changes in quality of life, including the dermatology Life Quality Index (DLQI)<br>","Secondary end point(s): - Change of PG-adapted RECIST criteria <br>- Wound Score and Visual Analogue Pain Scale from baseline to week 28<br>- The incidence and grading of adverse events and abnormal laboratory cytometry<br>- Cytokine expression of monocytes and T-cells <br>- Cytokine and immunohistological studies to analyze the cytokine profile in the punch biopsies of PG patients under Stelara® therapy <br>- Analysis of the phenotype and intracellular cytokine profile of Mononuclear cells and lymphocytes. ;Timepoint(s) of evaluation of this end point: week 16 and 28 ",StelaraPG01,"Janssen-Cilag GmbH",,Approved,27/12/2011,,,,,,,,,,,,"No results available","No results available","No results available",,,Yes,False,"          "
NCT01302795,"10 October 2016","Canakinumab for Pyoderma Gangrenosum","A Phase II Multi Center Open Label Pilot Study To Assess a Potential Effect of an Anti-Il-1-Beta Antagonist in the Treatment of Pyoderma Gangrenosum",,"University of Zurich",17/02/2011,"  20110217","10/03/2025 17:03:09",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT01302795,"Not recruiting",No,"18 Years","99 Years",Both,01/02/2011,5,Interventional,"Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment","Phase 2",Switzerland;Switzerland," ; ","Lars French, Prof MD;Lars French, Prof MD",,;,;,"University Hospital Zurich, Division of Dermatology;University Hospital Zurich, Division of Dermatology","<br>    Inclusion criteria: Patients fulfilling all of the following inclusion criteria may be<br>    enrolled in the study<br><br>     1. Age = 18 years of age at visit 0 and<br><br>     2. Subjects are capable of giving informed consent<br><br>     3. Non-healing ulcer with primarily neutrophil infiltration, regardless of size and<br>       location<br><br>     4. Diagnosis of pyoderma gangrenosum as confirmed by clinical and histological<br>       examination (see exclusion criteria). In case of doubt, a steering committee<br>       consisting of experts of the participating centers is going to evaluate whether<br>       inclusion is possible or not<br><br>    Exclusion criteria:<br><br>     - Other etiologies of ulcers 15, namely venous insufficiency, arterial occlusion,<br>       microcirculatory disorders, physical or chemical injury, infection, neuropathy,<br>       vasculitis, haematological disorders, neoplasia, other ulcerating diseases: Diseases<br>       with cutaneous manifestations mimicking pyoderma gangrenosum, including but not<br>       limited to Wegener's granulomatosis, polyarteritis nodosa, lymphoma, sporotrichosis<br>       and antiphospholipid syndrome.<br><br>     - Classical systemic therapy (including but not limited to: corticosteroids,<br>       methotrexate, mycophenolate mofetil, azathioprine, tacrolimus, dapsone,<br>       cyclophosphamide) affecting pyoderma gangrenosum less than 14 days prior to<br>       enrollment.<br><br>     - Therapy with other biologics (TNF antagonists, intravenous immunoglobulins) less than<br>       3 months or 5 half-lives prior to enrollment, whichever is longer.<br><br>     - Any other investigational drugs, other than investigational biologic treatment,<br>       within 30 days (or 3 months for investigational monoclonal antibodies) or 5<br>       half-lives prior to the baseline visit, whichever is longer. Washout period may be<br>       longer according to local requirements.<br><br>     - Topical therapy affecting pyoderma gangrenosum for a period of 14 days prior to<br>       enrollment.<br><br>     - Having a history of recurring bacterial, viral, fungal, atypical mycobacterial<br>       infection, especially active or latent granulomatous infections (incl. tuberculosis,<br>       histoplasmosis) or currently undergoing treatment for tuberculosis.<br><br>     - A positive quantiferon test indicating possible latent tuberculosis infection.<br><br>     - An abnormal chest x-ray indicating a possible infection or malignoma for a period of<br>       3 months prior to enrollment.<br><br>     - Known Human Immunodeficiency Virus (HIV)-, Hepatitis B (HBV)-, or Hepatitis C<br>       (HCV)-infection.<br><br>     - Having a severe medical condition that, in the judgment of the investigator, would<br>       jeopardize in any way the subject's safety following exposure to study drug.<br><br>     - Pregnant or lactating women, patients (men or women) planning a pregnancy during the<br>       duration of the study, lack of safe contraception.<br><br>    Safe contraception is defined as follows:<br><br>    Double-barrier contraception such as oral, injectable, or implantable contraceptives, or<br>    intrauterine contraceptive devices together with condom use.<br><br>    Both men and women must use safe contraception (double-barrier as defined above) during<br>    the duration of the study and until 6 months after the study.<br><br>    Please note that female subjects who are surgically sterilized/hysterectomized or<br>    post-menopausal for longer than 2 years are not considered as being of child bearing<br>    potential.<br><br>     - Having the presence or history of malignancy, including lymphoproliferative<br>       disorders. Subjects with a history of fully resolved basal or squamous cell skin<br>       cancer may be enrolled.<br><br>     - Contraindications to monoclonal or polyclonal antibodies, e.g. known hypersensitivity<br>       or allergy to class of drugs or the investigational product.<br><br>     - Known or suspected non-compliance, drug or alcohol abuse.<br><br>     - Inability to follow the procedures of the study, e.g. due to language problems,<br>       psychological disorders, dementia or confusional state of the subject.<br><br>     - Participation in another treatment study within the 30 days preceding and during the<br>       present study.<br><br>     - Previous enrollment into the current study.<br><br>     - Enrollment of the investigator, his/her family members, employees and other dependent<br>       persons.<br>   ;<br>    Inclusion criteria: Patients fulfilling all of the following inclusion criteria may be<br>    enrolled in the study<br><br>     1. Age = 18 years of age at visit 0 and<br><br>     2. Subjects are capable of giving informed consent<br><br>     3. Non-healing ulcer with primarily neutrophil infiltration, regardless of size and<br>       location<br><br>     4. Diagnosis of pyoderma gangrenosum as confirmed by clinical and histological<br>       examination (see exclusion criteria). In case of doubt, a steering committee<br>       consisting of experts of the participating centers is going to evaluate whether<br>       inclusion is possible or not<br><br>    Exclusion criteria:<br><br>     - Other etiologies of ulcers 15, namely venous insufficiency, arterial occlusion,<br>       microcirculatory disorders, physical or chemical injury, infection, neuropathy,<br>       vasculitis, haematological disorders, neoplasia, other ulcerating diseases: Diseases<br>       with cutaneous manifestations mimicking pyoderma gangrenosum, including but not<br>       limited to Wegener's granulomatosis, polyarteritis nodosa, lymphoma, sporotrichosis<br>       and antiphospholipid syndrome.<br><br>     - Classical systemic therapy (including but not limited to: corticosteroids,<br>       methotrexate, mycophenolate mofetil, azathioprine, tacrolimus, dapsone,<br>       cyclophosphamide) affecting pyoderma gangrenosum less than 14 days prior to<br>       enrollment.<br><br>     - Therapy with other biologics (TNF antagonists, intravenous immunoglobulins) less than<br>       3 months or 5 half-lives prior to enrollment, whichever is longer.<br><br>     - Any other investigational drugs, other than investigational biologic treatment,<br>       within 30 days (or 3 months for investigational monoclonal antibodies) or 5<br>       half-lives prior to the baseline visit, whichever is longer. Washout period may be<br>       longer according to local requirements.<br><br>     - Topical therapy affecting pyoderma gangrenosum for a period of 14 days prior to<br>       enrollment.<br><br>     - Having a history of recurring bacterial, viral, fungal, atypical mycobacterial<br>       infection, especially active or latent granulomatous infections (incl. tuberculosis,<br>       histoplasmosis) or currently undergoing treatment for tuberculosis.<br><br>     - A positive quantiferon test indicating possible latent tuberculosis infection.<br><br>     - An abnormal chest x-ray indicating a possible infection or malignoma for a period of<br>       3 months prior to enrollment.<br><br>     - Known Human Immunodeficiency Virus (HIV)-, Hepatitis B (HBV)-, or Hepatitis C<br>       (HCV)-infection.<br><br>     - Having a severe medical condition that, in the judgment of the investigator, would<br>       jeopardize in any way the subject's safety following exposure to study drug.<br><br>     - Pregnant or lactating women, patients (men or women) planning a pregnancy during the<br>       duration of the study, lack of safe contraception.<br><br>    Safe contraception is defined as follows:<br><br>    Double-barrier contraception such as oral, injectable, or implantable contraceptives, or<br>    intrauterine contraceptive devices together with condom use.<br><br>    Both men and women must use safe contraception (double-barrier as defined above) during<br>    the duration of the study and until 6 months after the study.<br><br>    Please note that female subjects who are surgically sterilized/hysterectomized or<br>    post-menopausal for longer than 2 years are not considered as being of child bearing<br>    potential.<br><br>     - Having the presence or history of malignancy, including lymphoproliferative<br>       disorders. Subjects with a history of fully resolved basal or squamous cell skin<br>       cancer may be enrolled.<br><br>     - Contraindications to monoclonal or polyclonal antibodies, e.g. known hypersensitivity<br>       or allergy to class of drugs or the investigational product.<br><br>     - Known or suspected non-compliance, drug or alcohol abuse.<br><br>     - Inability to follow the procedures of the study, e.g. due to language problems,<br>       psychological disorders, dementia or confusional state of the subject.<br><br>     - Participation in another treatment study within the 30 days preceding and during the<br>       present study.<br><br>     - Previous enrollment into the current study.<br><br>     - Enrollment of the investigator, his/her family members, employees and other dependent<br>       persons.<br>   ",,"Pyoderma Gangrenosum;Pyoderma Gangrenosum","Drug: Canakinumab;Drug: Canakinumab","Change of the Physician's global assessment (Grade 0-4) of the target lesion;Change of the Physician's global assessment (Grade 0-4) of the target lesion","Change in surface area of the target lesion of pyoderma gangrenosum;Change in surface area of the non-target lesions;Change in surface area of the target lesion of pyoderma gangrenosum;Change in surface area of the non-target lesions",DER-USZ-AAN-008;DER-USZ-AAN-008,"Please refer to primary and secondary sponsors;Please refer to primary and secondary sponsors",,,,,,,,,,,,,,,,,,,,No,False,"          "
EUCTR2008-008291-14-GB,"25 November 2019","Study of treatments in Pyoderma Gangrenosum patients - STOP GAP","Study of treatments in Pyoderma Gangrenosum patients - STOP GAP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ",,"Nottingham University Hospitals NHS Trust",22/05/2009,"  20090522","10/03/2025 17:03:09","EU Clinical Trials Register",https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-008291-14,"Not Recruiting",Yes,,,"<br> Female: yes<br> Male: yes<br>",14/05/2009,140,"Interventional clinical trial of medicinal product","<br>                Controlled: yes<br>                Randomised: yes<br>                Open: yes<br>                Single blind: no<br>                Double blind: no<br>                Parallel group: yes<br>                Cross over: no<br>                Other: yes<br>                Other trial design description: assesors of digital images (primary outcome measure) are blinded<br>                If controlled, specify comparator, Other Medicinial Product: yes<br>                Placebo: no<br>                Other: no<br>","
                Human pharmacology (Phase I): no
                Therapeutic exploratory (Phase II): no
                Therapeutic confirmatory - (Phase III): no
                Therapeutic use (Phase IV): yes
","Ireland;United Kingdom",,,,,,,"Inclusion criteria: <br>        •PG as diagnosed by the recruiting dermatologist. [An ulcerative lesion may have mixed aetiology, but provided the investigator has confidence that a clinical diagnosis of PG is appropriate then they are eligible. Other contributing factors and atypical features will be captured in the case report form].<br>        •Age over 18 years.<br>        •Able to provide written, informed consent.<br>        Presence of a measurable ulceration (e.g not pustular pyoderma gangrenosum)<br><br><br><br>        Are the trial subjects under 18? no<br>        Number of subjects for this age range:<br>        F.1.2 Adults (18-64 years) yes<br>        F.1.2.1 Number of subjects for this age range<br>        F.1.3 Elderly (>=65 years) yes<br>        F.1.3.1 Number of subjects for this age range<br>      ","Exclusion criteria: <br>        •Pregnant, lactating or at risk of pregnancy.<br>        •Granulomatous PG – this condition is very rare and may respond differently to treatment.<br>        •Hypersensitivity to study medication<br>        •Concomitant ciclosporin, prednisolone or IVIG therapy in the previous month.<br>        •Biopsy not consistent with PG.<br>        Biopsies will be used to exclude alternative aetiologies (e.g. malignancy, granulomatous PG, arteritis) rather than to confirm the diagnosis of PG, since histology is supportive rather than pathognomic. Ideally, the biopsy will be a 1.5cm rectangular biopsy taken through the edge of the ulcer and left to granulate and heal by secondary intention. Alternatively, 2 separate punch biopsies done at the edge of the ulcer and at the extending margin may be used. It is not normal practice to await histological confirmation before initiating therapy, so patients will be randomised prior to receiving histological results. If the histology indicates an alternative aetiology, the participant will be excluded at that time.<br>        •Clinically significant renal impairment, such that you would not normally treat the patient with either prednisolone or ciclosporin<br>        •Any pre-treatment investigations, the results of which would prompt you not to use prednisolone or ciclosporin<br>        •A diagnosis of malignancy or pre-malignant disease where prednisolone or ciclosporin might interfere with ongoing therapy or might cause harm<br>        •The patient has a concurrent medical condition that means that you would not normally treat the patient with either prednisolone or ciclosporin (e.g a degree of hypertension that would lead to not using either of the study drugs, advanced heart failure, poorly controlled diabetes, history of peptic ulcer, malignancy in previous years)<br>        •Already participating in another clinical trial.<br><br>      ","pyoderma gangrenosum <br>        MedDRA version: 14.0        Level: LLT        Classification code 10037634        Term: Pyoderma gangenosum        System Organ Class: 10040785 - Skin and subcutaneous tissue disorders       <br>        MedDRA version: 14.0        Level: PT        Classification code 10037635        Term: Pyoderma gangrenosum        System Organ Class: 10040785 - Skin and subcutaneous tissue disorders      ","<br>        Trade Name: Neoral soft gelatin capsules<br>        Pharmaceutical Form: Capsule, soft<br>        INN or Proposed INN: CICLOSPORIN<br>        CAS Number: 59865133<br><br>        Trade Name: Neoral Oral Solution<br>        Pharmaceutical Form: Oral solution<br>        INN or Proposed INN: CICLOSPORIN<br>        CAS Number: 59865133<br><br>        Product Name: Prednisolone<br>        Pharmaceutical Form: Tablet<br>        INN or Proposed INN: PREDNISOLONE<br>        CAS Number: 50248<br><br>        Product Name: Prednisolone<br>        Pharmaceutical Form: Soluble tablet<br>        INN or Proposed INN: PREDNISOLONE<br>        CAS Number: 50248<br><br>        Product Name: Prednisolone<br>        Pharmaceutical Form: Coated tablet<br>        INN or Proposed INN: PREDNISOLONE<br>        CAS Number: 50248<br><br>","<br>        Secondary Objective: •To assess time to complete healing<br>        •To assess the safety and tolerability of the compared treatments.<br>        •To assess the cost-effectiveness of the compared treatments.<br>      ;<br>        Main Objective: To evaluate the efficacy and safety of the two most commonly used systemic treatments for PG. The study aims to test the hypothesis that systemic ciclosporin (4 mg/kg/day) is more effective than systemic prednisolone (0.75 mg/kg/day) for oral therapy of PG.<br><br>        Primary objective: To assess the speed of response to treatment - assessed by digital images at 6 weeks.<br>      ;<br>        Primary end point(s): •Velocity of healing.<br>        This will be captured for a single target lesion per patient and measured using digital photography and VEV computerised planimetry. If multiple lesions are present, the target lesion for study will be the largest of those present. Digital images will be taken at baseline and at 6 weeks. In addition, maximum length in the longest axis and maximum width at right angles to this axis will be measured in order to provide some measure of improvement in case of difficulties with the digital images. This will be converted to approximate area by the formula: length x width x 0.785, which approximates to an ellipse for the purpose of randomisation and analysis.<br><br>        This outcome has been chosen as the primary outcome measure as it is<br>        1) unlikely to be compromised by the single-blind nature of the study<br>        2) should result in complete data for almost all participants<br>        3) does not require lengthy follow-up and<br>        4) previous work in patients with venous leg ulcers would suggest that velocity of healing is a good surrogate for subsequent healing.<br>      ",,UKDCTN0901,,,Approved,01/01/1900,,,,,Yes,15/08/2016,https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-008291-14/results,,31/01/2013,,,https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-008291-14/results#baselineCharacteristicsSection,https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-008291-14/results#adverseEventsSection,https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-008291-14/results#endPointsSection,,,No,"True ","parent    "
NCT00791557,"19 October 2017","Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease","An Open Label Single Center Pilot Study Investigating the Clinical Response and Mechanism of Action of Infliximab in the Treatment of Adults With Inflammatory Bowel Disease Who Have Moderate to Severe Pyoderma Gangrenosum",,"University Hospitals Cleveland Medical Center",13/11/2008,"  20081113","10/03/2025 17:03:09",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT00791557,"Not recruiting",No,"18 Years","75 Years",All,01/10/2008,2,Interventional,,N/A,"United States;United States;United States;United States"," ; ; ; ","Neil J Korman, MD.PhD;Neil J Korman, MD.PhD;Neil J Korman, MD.PhD;Neil J Korman, MD.PhD",,;;;,;;;,"University Hospitals Cleveland Medical Center;University Hospitals Cleveland Medical Center;University Hospitals Cleveland Medical Center;University Hospitals Cleveland Medical Center","<br>    Inclusion Criteria:<br><br>     - Must Be ages 18-75<br><br>     - Must have both inflammatory bowel disease and moderate to severe pyoderma gangrenosum<br><br>     - Must never have received Infliximab for the treatment of pyoderma gangrenosum<br><br>    Exclusion Criteria:<br><br>     - Have had any previous treatment with monoclonal antibodies other than infliximab used<br>       to treat IBD or antibody fragments.<br><br>     - Have a history of serious infections<br>   ;<br>    Inclusion Criteria:<br><br>     - Must Be ages 18-75<br><br>     - Must have both inflammatory bowel disease and moderate to severe pyoderma gangrenosum<br><br>     - Must never have received Infliximab for the treatment of pyoderma gangrenosum<br><br>    Exclusion Criteria:<br><br>     - Have had any previous treatment with monoclonal antibodies other than infliximab used<br>       to treat IBD or antibody fragments.<br><br>     - Have a history of serious infections<br>   ;<br>    Inclusion Criteria:<br><br>     - Must Be ages 18-75<br><br>     - Must have both inflammatory bowel disease and moderate to severe pyoderma gangrenosum<br><br>     - Must never have received Infliximab for the treatment of pyoderma gangrenosum<br><br>    Exclusion Criteria:<br><br>     - Have had any previous treatment with monoclonal antibodies other than infliximab used<br>       to treat IBD or antibody fragments.<br><br>     - Have a history of serious infections<br>   ;<br>    Inclusion Criteria:<br><br>     - Must Be ages 18-75<br><br>     - Must have both inflammatory bowel disease and moderate to severe pyoderma gangrenosum<br><br>     - Must never have received Infliximab for the treatment of pyoderma gangrenosum<br><br>    Exclusion Criteria:<br><br>     - Have had any previous treatment with monoclonal antibodies other than infliximab used<br>       to treat IBD or antibody fragments.<br><br>     - Have a history of serious infections<br>   ",,"Pyoderma Gangrenosum;Crohn's Disease;Ulcerative Colitis;Inflammatory Bowel Disease;Pyoderma Gangrenosum;Crohn's Disease;Ulcerative Colitis;Inflammatory Bowel Disease;Pyoderma Gangrenosum;Crohn's Disease;Ulcerative Colitis;Inflammatory Bowel Disease;Pyoderma Gangrenosum;Crohn's Disease;Ulcerative Colitis;Inflammatory Bowel Disease","Drug: Infliximab;Drug: Infliximab;Drug: Infliximab;Drug: Infliximab","The Efficacy of Infliximab in Pyoderma Gangrenosum in Adult Subjects Who Have Inflammatory Bowel Disease;The Efficacy of Infliximab in Pyoderma Gangrenosum in Adult Subjects Who Have Inflammatory Bowel Disease",,06-07-14,"Please refer to primary and secondary sponsors","Centocor, Inc.",,,,,,,Yes,15/11/2013,https://clinicaltrials.gov/ct2/show/results/NCT00791557,,,,,,,,,,No,False,"          "
NCT00730717,"21 February 2022","Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum","Multi Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum",,"Wright State University",04/08/2008,"  20080804","10/03/2025 17:03:09",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT00730717,"Not recruiting",No,"18 Years",N/A,All,01/05/2009,0,Interventional,"Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2","United States"," ","David F Fiorentino, MD, PhD",,,,"Stanford University","<br>    Inclusion Criteria:<br><br>     - Subject is willing and able to give informed consent.<br><br>     - Subject is willing and able to participate in the study as an outpatient and is<br>       willing to comply with study requirements.<br><br>     - Subject is 18 years of age or older.<br><br>     - Subject has a diagnosis of pyoderma gangrenosum that involves total area of 3 cm2 or<br>       greater and is of sufficient severity to warrant systemic agents.<br><br>     - If female of childbearing potential, subject will have a negative urine pregnancy test<br>       at Screening and Week 0.<br><br>     - If female, subject will be either post-menopausal for > 1 year, surgically sterile<br>       (hysterectomy or bilateral tubal ligation), or practicing one form of birth control<br>       (abstinence, oral contraceptive, estrogen patch, implant contraception, injectable<br>       contraception, IUD, diaphragm, condom, sponge, spermicides, or vasectomy of partner).<br>       Female subjects will continue to use contraception for 6 months following the last<br>       injection.<br><br>     - Screening laboratory results are within the following parameters:<br><br>        - Hemoglobin > 9 g/dL<br><br>        - White blood cells > 3.0 x 10 to the 9th power/L, <14.0 x 10 to the 9th power/L<br>         (unless on oral corticosteroids and no signs/symptoms of infection)<br><br>        - Neutrophils > 1.5 x 10 to the 9th power/L<br><br>        - Platelets > 100 x 10 to the 9th power/L<br><br>        - Lymphocytes > 0.5 x 10 to the 9th power/L<br><br>        - Serum creatinine within 1.5 times the upper limit of normal range<br><br>        - AST and ALT within 2 times the upper limit of normal range<br><br>        - Subject has been on a stable dose of antibiotics, oral corticosteroids or other<br>         immunosuppressives, such cyclosporine, tacrolimus, azathioprine, methotrexate, or<br>         mycophenolate mofetil over the previous 4 weeks<br><br>    Exclusion Criteria:<br><br>     - Subject has evidence of a clinically significant, unstable or poorly controlled<br>       medical condition.<br><br>     - Subject has a chest X-ray consistent with an active infection or previous exposure to<br>       TB and/or a positive purified protein derivative test at screening (>5 mm). (Subjects<br>       may participate if they are being actively treated in accordance with CDC guidelines.)<br><br>     - Subject has a serious, active or recurrent bacterial, viral, or fungal infection. This<br>       includes hepatitis B and C, and HIV.<br><br>     - Subject has been hospitalized for infection or received IV antibiotics within the<br>       previous 2 months prior to baseline.<br><br>     - Subject has clinical evidence as determined by the investigator of acutely infected<br>       pyoderma gangrenosum or subject is receiving systemic antibiotics for the treatment of<br>       acute infection. Subjects receiving minocycline, tetracycline, dapsone, or other<br>       antibiotics for anti-inflammatory purposes are permitted.<br><br>     - Subject has a history of tuberculosis without documented adequate therapy.<br><br>     - Subject has a history of a central nervous system disorder/demyelinating disease or<br>       symptoms suggestive of multiple sclerosis or optic neuritis.<br><br>     - Subject has current signs or symptoms or history of systemic lupus erythematosus.<br><br>     - Subject has been diagnosed with a malignancy within the past 5 years except for<br>       successfully treated non-melanoma skin cancer.<br><br>     - Subject has signs or symptoms suggestive of a possible lymphoproliferative disease.<br><br>     - Subject has a diagnosis of severe congestive heart failure (Class III or IV NYHA).<br><br>     - Subject has had a substance abuse problem within the previous 3 years.<br><br>     - Subject has been treated with an anti-TNF biologic immune response modifier, such as<br>       infliximab, adalimumab, or etanercept within the past 8 weeks.<br><br>     - Subject has any dermatologic disease in the target site that may be exacerbated by<br>       treatment or interfere with examination.<br><br>     - Subject has been administered an investigational drug in another clinical study within<br>       30 days prior to baseline (or 5 half-lives, whichever is longer).<br><br>     - Subject has a known allergy to adalimumab.<br><br>     - Subject is female and is pregnant, is considering becoming pregnant during the study<br>       and for 6 months afterwards, or is nursing.<br>   ",,"Pyoderma Gangrenosum","Drug: Humira;Drug: Humira","Mean change in the number of ulcers from baseline to the end of study;Mean change in ulcer area from baseline to end of study","Number of complete responders, partial responders, minimal responders and non-responders at the end of study.;Mean change in the number of ulcer by visit;Mean change in the ulcer area from baseline by visit;Mean change in subject's evaluation of severity measured by visual analogue scale;Mean change in subject's evaluation of pain by visual analogue scale;Mean change in undermining score;Change in dose of antibiotics and immunosuppressives used to treat PG","HUM 04-37","Please refer to primary and secondary sponsors","Stanford University;Wake Forest University Health Sciences",,,,,,,,,,,,,,,,,,,Yes,False,"          "
NCT00690846,"12 December 2020","Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum","A Multi-Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum (HUM 04-37)",,"Wake Forest University Health Sciences",02/06/2008,"  20080602","10/03/2025 17:03:09",ClinicalTrials.gov,https://clinicaltrials.gov/show/NCT00690846,"Not recruiting",No,"18 Years",N/A,All,01/07/2007,0,Interventional,"Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). ","Phase 2","United States"," ","Joseph Jorizzo, MD",,,,"Wake Forest University Health Sciences","<br>    Inclusion Criteria:<br><br>     - Subject is willing and able to give informed consent.<br><br>     - Subject is willing and able to participate in the study as an outpatient and is<br>       willing to comply with study requirements.<br><br>     - Subject is 18 years of age or older.<br><br>     - Subject has a diagnosis of pyoderma gangrenosum that involves total area of 3 cm2 or<br>       greater and is of sufficient severity to warrant systemic agents.<br><br>     - If female of childbearing potential, subject will have a negative urine pregnancy test<br>       at Screening and Week 0.<br><br>     - If female, subject will be either post-menopausal for > 1 year, surgically sterile<br>       (hysterectomy or bilateral tubal ligation), or practicing one form of birth control<br>       (abstinence, oral contraceptive, estrogen patch, implant contraception, injectable<br>       contraception, IUD, diaphragm, condom, sponge, spermicides, or vasectomy of partner).<br>       Female subjects will continue to use contraception for 6 months following the last<br>       injection.<br><br>     - Screening laboratory results are within the following parameters:<br><br>     - Subject has been on a stable dose of antibiotics, oral corticosteroids or other<br>       immunosuppressives, such cyclosporine, tacrolimus, azathioprine, methotrexate, or<br>       mycophenolate mofetil over the previous 4 weeks<br><br>    Exclusion Criteria:<br><br>     - Subject has evidence of a clinically significant, unstable or poorly controlled<br>       medical condition.<br><br>     - Subject has a chest X-ray consistent with an active infection or previous exposure to<br>       TB and/or a positive purified protein derivative test at screening (>5 mm). (Subjects<br>       may participate if they are being actively treated in accordance with CDC guidelines.)<br><br>     - Subject has a serious, active or recurrent bacterial, viral, or fungal infection. This<br>       includes hepatitis B and C, and HIV.<br><br>     - Subject has been hospitalized for infection or received IV antibiotics within the<br>       previous 2 months prior to baseline.<br><br>     - Subject has clinical evidence as determined by the investigator of acutely infected<br>       pyoderma gangrenosum or subject is receiving systemic antibiotics for the treatment of<br>       acute infection. Subjects receiving minocycline, tetracycline, dapsone, or other<br>       antibiotics for anti-inflammatory purposes are permitted.<br><br>     - Subject has a history of tuberculosis without documented adequate therapy.<br><br>     - Subject has a history of a central nervous system disorder/demyelinating disease or<br>       symptoms suggestive of multiple sclerosis or optic neuritis.<br><br>     - Subject has current signs or symptoms or history of systemic lupus erythematosus.<br><br>     - Subject has been diagnosed with a malignancy within the past 5 years except for<br>       successfully treated non-melanoma skin cancer.<br><br>     - Subject has signs or symptoms suggestive of a possible lymphoproliferative disease.<br><br>     - Subject has a diagnosis of severe congestive heart failure (Class III or IV NYHA).<br><br>     - Subject has had a substance abuse problem within the previous 3 years.<br><br>     - Subject has been treated with an anti-TNF biologic immune response modifier, such as<br>       infliximab, adalimumab, or etanercept within the past 8 weeks.<br><br>     - Subject has any dermatologic disease in the target site that may be exacerbated by<br>       treatment or interfere with examination.<br><br>     - Subject has been administered an investigational drug in another clinical study within<br>       30 days prior to baseline (or 5 half-lives, whichever is longer).<br><br>     - Subject has a known allergy to adalimumab.<br><br>     - Subject is female and is pregnant, is considering becoming pregnant during the study<br>       and for 6 months afterwards, or is nursing.<br>   ",,"Pyoderma Gangrenosum","Drug: adalimumab","Mean change in the number of ulcers.",,32410;IRB00002156,"Please refer to primary and secondary sponsors",,,,,,,,,,,,,,,,,,,,No,False,"          "
